

Chapter 2

The Role of Carbon Monoxide as a Gasotransmitter in Cardiovascular and Metabolic Regulation

Ashley A. Untereiner, Lingyun Wu and Rui Wang

Abstract Carbon monoxide (CO) is produced endogenously through the oxidative catabolism of heme by heme oxygenase (HO). First described as a putative neuronal signaling messenger, CO is now also known to be involved in a variety of physiological and pathophysiological processes in the cardiovascular system, including regulating blood pressure, smooth muscle cell proliferation, anti-inflammatory, anti-apoptotic, and anti-coagulation effects. CO contributes substantially to the protective effects of HO enzymes as a mediator of cell and tissue protection. The diverse actions of this diatomic gas mainly depend on the stimulation of soluble guanylate cyclase, opening of BK_{Ca} channels as well as activation of mitogen-activated protein kinases, and/or Akt signaling pathways. The cellular and molecular consequences of CO signaling are only partially characterized and appear to differ depending on cell types and circumstances. This chapter provides an overview of the many roles CO plays as a gasotransmitter in the cardiovascular system.

Keywords Carbon monoxide • Heme oxygenase • Cardiovascular • Gasotransmitter • Signal transduction systems

A. A. Untereiner · L. Wu
Department of Health Sciences, Lakehead University,
Thunder Bay, ON P7B 5E1, Canada

A. A. Untereiner · L. Wu
Thunder Bay Regional Research Institute,
Thunder Bay, ON, Canada

R. Wang (✉)
Department of Biology, Lakehead University, 955 Oliver Road,
Thunder Bay, ON P7B 5E1, Canada
e-mail: rwang@lakeheadu.ca

Abbreviations

AMPK	AMP-activated protein kinase
BK _{Ca}	Big-conductance calcium-activated potassium channels
C/EBP	CCAATT-enhancer-binding protein
cGMP	Cyclic guanosine 3', 5'-monophosphate
CO	Carbon monoxide
CoPP	Cobalt protoporphyrin
CORM	Carbon monoxide releasing molecule
EDRF	Endothelium-derived relaxing factor
ENaC	Epithelial Na ⁺ channel
eNOS	Endothelial nitric oxide synthase
ER	Endoplasmic reticulum
ERK	Extracellular regulated kinases
ETC	Electron transport chain
GC	Guanylate cyclase
H ₂ O ₂	Hydrogen peroxide
H ₂ S	Hydrogen sulfide
HEK293	Human embryonic kidney
HIF-1 α	Hypoxia-inducible factor-1 α
HO	Heme oxygenase
HUVEC	Human umbilical vein endothelial cells
ICAM-1	Intracellular adhesion molecule-1
IL	Interleukin
iNOS	Inducible nitric oxide synthase
JNK	Jun-activated kinases
LPS	Lipopolysaccharide
MAPK	Mitogen-activated protein kinases
NF- κ B	Nuclear factor- κ B
NO	Nitric oxide
NOS	Nitric oxide synthase
Nox	Nicotinamide adenine dinucleotide phosphate oxidase
O ₂ ⁻	Superoxide anion
PAH	Pulmonary arterial hypertension
PI3K	Phosphatidylinositol 3-kinase
PPAR γ	Peroxisome proliferator-activated receptor- γ
ROS	Reactive oxygen species
sGC	Soluble guanylate cyclase
SHRs	Spontaneously hypertensive rats
STATs	Signal transducers and activators of transcription
STZ	Streptozotocin
TLR	Toll-like receptor
VEGF	Vascular endothelial growth factor
VSMCs	Vascular smooth muscle cells
ZDF	Zucker diabetic fatty

2.1 Introduction

For almost a century, carbon monoxide (CO) has been commonly stigmatized as the “silent killer” due to its strong affinity to hemoglobin (Douglas et al. 1912; Haldane 1927), 240 times that of oxygen, resulting in tissue hypoxia and death (Weaver 1999; Gorman et al. 2003; Von Berg 1999). Because of its association as a toxic gas, it would not be until 1968 when it was proposed that CO is endogenously produced from heme catalysis (Tenhunen et al. 1968). Not understanding the significance of this discovery at the time, the endogenous synthesis of CO was seen as a metabolic waste product of heme oxygenase (HO)-catalyzed heme degradation (Barinaga 1993). However, the breakthrough discovery detailing the possible physiological role CO may play in the mammalian system came in 1987 when Brune and Ullrich (1987) showed that, like nitric oxide (NO), CO can also activate soluble guanylate cyclase (sGC). This laid the foundation for the next discovery in 1993 where Synder and associates (1993) (Verma et al. 1993) showed that CO, again like NO, might also have a physiological role to play. Since then, there have been numerous findings of CO having anti-inflammatory, anti-apoptotic, and anti-proliferative properties [for review see (Wu and Wang 2005)]. This chapter will focus on the signaling targets of CO contributing to its physiological and pathophysiological role in the cardiovascular system.

2.2 How the Concept of “Gasotransmitter” Evolved

The scientific community was thrilled when the final verdict of the mysterious endothelium-derived relaxing factor (EDRF), a vasorelaxant substance synthesized and secreted from endothelial cells, was a gaseous molecule (Furchgott and Zawadzki 1980). The conclusion that NO is an endogenous gaseous molecule, termed gasotransmitter, triggered the exploration of other possible gasotransmitters, including CO and H₂S (Wang 2002). Unlike neurotransmitters, gasotransmitters are not stored in vesicles, thus they must be rapidly synthesized in response to stimulation. There is no exocytosis upon the release of gasotransmitters, and in fact, gases are not contained by membranes at all; they can freely enter a cell with no need for receptors or active endocytosis to influence a cell.

The discovery of NO, CO, and H₂S as small signaling gasotransmitters has spawned a new type of science: that endogenously derived gases could elicit crucial biological functions, as well as contribute to the pathogenesis of human diseases. Several other gases are currently under investigation to determine if they too act as endogenous mediators, including acetaldehyde (CH₃CHO), sulfur dioxide (SO₂), dinitrogen oxide (N₂O), and ammonia (NH₃). Overall, these new insights have improved our understanding of physiological importance of gasotransmitters not only in physiological functions, but also in the pathogenesis of human diseases.

Table 2.1 Classification of the gasotransmitter

-
1. They are to be small molecules of gas, such as NO, CO, and H₂S^a
 2. The gasotransmitter must be membrane permeable and not have to rely on cell membrane cognate receptors, nor vesicle-releasing machinery to elicit their cell signaling response
 3. The gaseous substance must be endogenously and enzymatically synthesized and its formation must be regulated by a physiological stimuli
 4. The biological effects of gasotransmitters can be mimicked by the same molecules applied exogenously
 5. They must have specific cellular and molecular targets. To illustrate this, both NO and CO can activate GC thus increasing the intracellular concentrations of the secondary messenger cGMP and H₂S can induce the opening probability of K_{ATP} channels in vascular tissues
 6. Finally, the cellular effects of gasotransmitters may or may not be mediated by second messengers
-

^a The molar mass of NO, CO, and H₂S are 30.01, 28.01, and 34.08 g mol⁻¹, respectively

2.3 Classification of a Gasotransmitter

Before the discovery of NO in 1980 (Furchgott and Zawadzki 1980) the idea that a gaseous substance can induce an array of cell signaling processes, such as the regulation of cardiovascular, immune and nervous system function, was unfathomable. The concept and terminology of ‘gasotransmitter’ was firstly proposed by Wang (2002), which implies a class of endogenous gaseous substances that can induce an array of signaling responses in a cell. Now with this new science, standards must be laid out to distinguish a gasotransmitter so it may not be confused with other classifications of signaling molecules. The criteria for establishing a signaling molecule as a gasotransmitter are described in Table 2.1 (Wu and Wang 2005; Wang 2002).

One of the most intriguing features of gasotransmitters corresponds to their unique chemical signaling mechanism. Unlike classic signaling molecules that interact through the stimulation of G protein coupled receptors or tyrosine kinase receptors to elicit their distinct signaling cascade, gasotransmitters chemically modify their intracellular targets. For instance, NO and H₂S induce S-nitrosylation or S-sulphydration of the targeted protein, respectively. Through post-translational modification, gasotransmitters are able to induce immediate effects in the targeted cell. This chapter will solely look at the signaling process of CO. If the reader wishes to learn about the signaling process of NO and H₂S, they are invited to read other excellent reviews (Mustafa et al. 2009; Li et al. 2009) or consult the other chapters in this book.

2.3.1 CO as a Gasotransmitter

As a small molecule of gas, CO can freely pass through cell membranes without having to rely on the assistance of the targeted cell’s transportation machinery. This allows CO to rapidly influence cellular behavior and function. CO is

endogenously synthesized by HO. There are currently three known isoforms of HO, including HO-1, HO-2 and HO-3. These isoforms are discussed in detail in the following section.

Unlike NO and H₂S, gaseous CO is not metabolized in mammals (Motterlini and Otterbein 2010; Leffler et al. 2006). In fact, elimination of CO is strictly through exhalation in the lungs without biochemical modification (Kreck et al. 2001). Under normoxic conditions, this diatomic gas has a half life of 3–7 h (Motterlini and Otterbein 2010). Indeed, out of all three gases CO is the most biologically stable gasotransmitter. CO has weak chemical reactivity, mainly because it does not have unpaired electrons, and does not chemically dissociate in an aqueous solution to form different chemical species. Thus, CO might be capable of exerting its effects during longer time periods and distances compared to NO or H₂S.

2.4 Production of CO in the Cardiovascular System

Long before the concept of gasotransmitters was even established (Wang 2002), the scientific community was aware that living organisms can endogenously synthesize CO (Sjöstrand 1949, 1951; Coburn et al. 1963). In the presence of O₂ and NADPH, the endogenous production of CO raises principally from the catabolism of heme by HO (~86 %) to subsequently give equimolar amounts of biliverdin, Fe^{II}, and CO (Tenhunen et al. 1969) (Fig. 2.1). All of these three products of HO are biologically active. Biliverdin formed in this reaction is reduced to bilirubin by biliverdin reductase (Abraham and Kappas 2008). HO catalyzes the rate-limiting step in the degradation of heme to CO and biliverdin (Tenhunen et al. 1969). Although most of the heme oxidation occurs in the liver and spleen, HO is ubiquitously expressed in mammalian cells (Tenhunen et al. 1968). This gives HO the potential to continuously produce CO (Tenhunen et al. 1968).

As mentioned in the previous section, there are three mammalian paralogues of HO. These isoforms of HO are sub-classified into either inducible (HO-1) by inflammation or oxidative stress, or constitutive (HO-2), meaning they are constantly active (Abraham and Kappas 2008). The inducible HO-1 is a redox-sensitive response protein whose activity is up-regulated by enhanced oxidative stress (Maines 1997), either by inflammatory or disease-like conditions. Furthermore, HO-1 is a heat-shock protein (Shibahara and Müller 1987; Okinaga and Shibahara 1993) and is considered to be an essential antioxidant enzyme up-regulated in response to cellular stress (Abraham and Kappas 2008). On the other hand, HO-2 is constitutively expressed and is mainly responsible for basal HO activity (Abraham and Kappas 2008; Abraham et al. 2003), and thus CO production. HO-2 is activated by calcium-calmodulin (Boehning et al. 2004), as well as casein kinase 2 in neurons (Boehning et al. 2003). Similar to eNOS, HO-2 is also localized to the endothelial layer of blood vessels (Zakhary et al. 1996); where like NO and H₂S, CO too plays an important physiological role in the regulation of vascular tone (Wang 1998).



Fig. 2.1 Endogenous production of CO from heme oxygenase

Although ubiquitously expressed in all tissues examined so far, there is particularly a high density of these enzymes in the brain (HO-2), liver (HO-2 and HO-1), spleen (HO-1), vascular endothelial cells, and smooth muscle cells (HO-1 and HO-2) (Abraham and Kappas 2008). Likewise, these tissues are also central to erythrocyte turnover and contain large heme pools, further contributing to the enhanced carboxy hemoglobin levels detected in these tissue beds. Finally, HO-3 appears to be an inactive paralogue and is so far thought to represent a pseudogene (Hayashi et al. 2004). HO-3 was cloned from rat brain, but other than that, not much is currently known about the HO-3 isoform (McCoubrey et al. 1997).

The remaining 14 % of CO production lies within lipid peroxidation, bacteria, photo-oxidation, and xenobiotic (foreign compound) metabolism (Vreman et al. 2001). Ideally, healthy humans produce about $20 \mu\text{M h}^{-1}$ of CO (Marks et al. 1991; Stocker et al. 1987; McDonagh 1990); however, elevated levels of exhaled CO from critically ill patients have been observed in conditions of asthma (Zayasu et al. 1997; Horvath et al. 1998), bronchiectasis (Horvath et al. 1998), cystic fibrosis (Antuni et al. 2000; Paredi et al. 2000), upper (Yamaya et al. 1998) and lower (Biernacki et al. 2001) respiratory tract viral infections, diabetes (Paredi et al. 1999), rhinitis (Monma et al. 1999), and metabolic syndrome (Cheng et al. 2010). Major emphasis will be focused on cardiovascular-related diseases in this chapter.

2.5 Physiological Functions of CO in the Cardiovasculature

The diverse actions of CO have been mainly attributed to its regulation of common signaling pathways, such as the stimulation of sGC, opening of BK_{Ca} channels, activation of mitogen-activated protein kinases (MAPK), and Akt. The signaling outcomes of this activation largely depend on cell types and circumstances.

2.5.1 CO-Mediated Vasorelaxation

CO stimulates vasorelaxation mainly through three major cellular mechanisms. These include the activation of sGC (Ramos et al. 1989; Achouh et al. 2008; Suematsu et al. 1995), stimulation of big-conductance calcium-activated potassium channels (BK_{Ca}) (Li et al. 2008; Dubuis et al. 2005), as well as NOS induction

(Foresti et al. 2004; Botros and Navar 2006). The interaction between the CO/HO and NO/NOS systems are discussed in further detail in Sect. 2.8.

CO releasing molecules (CORMs) were shown to relax precontracted aortic rings (Foresti et al. 2004), dilate renal afferent arterioles (Botros and Navar 2006), decrease intrahepatic vascular resistance, and increase perfusion flow in cirrhotic livers (Van Landeghem et al. 2009). CO can also indirectly reduce vascular resistance by blocking the synthesis of the potent vasoconstrictors, including endothelin-1 (Morita and Kourembanas 1995) and the cytochrome P450-mediated generation of vasoconstrictors (Kaide et al. 2004; Estabrook et al. 1970).

Under oxidative stress, CO may act as a vasoconstrictor (Lamon et al. 2009). Both bubbled CO and CORM-3 constricted rat renal arteries, whereby antioxidants (e.g. tempol and ebselen) inhibited CO-induced reactive oxygen species (ROS) production and converted CO from constrictor to dilator (Lamon et al. 2009). Furthermore, inhibition of the pro-oxidant enzymes, such as NOS, NADPH oxidase (Nox), xanthine oxidase, and complex IV of the mitochondrial electron chain, converted CO from constrictor to dilator (Lamon et al. 2009). Thus, the redox state of the cell may play a key role in determining whether CO induces vasodilation or vasoconstriction; thereby, allowing CO to contribute to the fine-tuning of vascular tone.

2.5.2 CO Effects on Cell Proliferation and Apoptosis

2.5.2.1 Anti-Apoptotic Effects of CO

The effects of CO signaling on cellular apoptosis are tissue and cell specific. For instance, CO acts as an anti-apoptotic agent in endothelial cells (Brouard et al. 2000; Kim et al. 2007), hepatocytes (Kim et al. 2008; Choi et al. 2003), and cardiomyocytes (Clark et al. 2003), thus preventing cell and tissue injury. The anti-apoptotic effects of CO appear to be dependent on the activation of the p38 MAPK signaling transduction pathway (Brouard et al. 2000; Kim et al. 2007), phosphorylation of protein kinase R-like endoplasmic reticulum kinase, and/or through Akt activation (Kim et al. 2008). CO was shown to prevent tumor necrosis factor-(TNF)- α -induced cellular apoptosis (Brouard et al. 2000) and endoplasmic reticulum (ER) stress-induced apoptosis (Kim et al. 2007) via a p38 MAPK-dependent mechanism. Additionally, CO protected hepatocytes against apoptosis and fulminant hepatitis through the activation of nuclear factor (NF)- κ B via ROS generation and Akt pathways in primary rat or mouse hepatocytes and Hep3B cells (a human hepatoma cell line) (Kim et al. 2008). Interestingly, low CO concentrations (10–100 μ M) can prevent mitochondrial membrane permeabilization in isolated mouse hepatocytes, thus blocking the release of pro-apoptotic factors (Queiroga et al. 2011); however, high CO concentrations (250–500 μ M) triggered mitochondrial swelling (Queiroga et al. 2011). It remains to be seen if therapeutic application of CO also elicits these pathways observed under in vitro analysis.

2.5.2.2 Pro-Apoptotic Effects of CO

The pro-apoptotic effect of CO was seen in hyperproliferative smooth muscle cells (Zheng et al. 2009; Peyton et al. 2002) and fibroblasts (Zhou et al. 2005). CO also inhibits the proliferation of human airway smooth muscle cells (Song et al. 2002) and rat vascular smooth muscle cells under both hypoxic (Morita and Kourembanas 1995; Morita et al. 1997) and normoxic (Morita et al. 1997) conditions. Zhou et al. (2005) demonstrated that both chronic (14 days) and transient exposure (3 h) of inhaled CO (250 ppm) to mice inhibited fibroblast proliferation, thus reducing the degree of fibrosis. The authors showed that CO arrested fibroblast proliferation at the G0/G1 phase of the cell cycle through a cGMP-dependent mechanism that involved changes in the expression of cell-cycle regulatory proteins (increased cellular levels of the cyclin-dependent kinase inhibitor, p21Cip1, and decreased levels of cyclins A and D) (Zhou et al. 2005). Peyton et al. (2002) reported that 100–200 ppm CO arrested serum-stimulated vascular smooth muscle cell (VSMC) proliferation at the G(1)/S transition phase and blocked the expression of cyclin A, as well as the activation of cyclin A-associated kinase and cyclin-dependent kinase 2. Likewise, 250 ppm CO inhibited α -smooth muscle actin proliferation through enhanced expression of small proline-rich protein-1 A expression via stimulation of the extracellular regulated kinases (ERK) pathway (Zheng et al. 2009). It is becoming increasingly clear that the HO/CO signaling system is an important mediator in regulating cell survival.

2.5.3 CO-Mediated Anti-Aggregatory Effects

In addition to regulating cell growth and relaxing blood vessels, CO may also preserve blood flow at sites of vascular damage by blocking platelet aggregation. Monolayers of cultured rat aortic VSMCs subjected to shear stress stimulated time-dependent increases in the inducible HO-1, the production and release of CO, as well as increases in intracellular cGMP levels in co-incubated platelets (Wagner et al. 1997). The authors showed that treatment with the HO-1 inhibitor (30 μ M SnPP-IX) blocked the stimulatory effect on platelet cGMP concentration induced by sheared VSMCs (Wagner et al. 1997). Likewise, CO was shown to inhibit the production of platelet-derived growth factor-B in endothelial cells under hypoxic conditions (Morita and Kourembanas 1995).

These results suggest that CO is an endogenous VSMC-derived messenger that may be selectively induced by hemodynamic forces to block platelet aggregation and preserve blood flow at sites of vascular damage. Further investigation is needed to elucidate the actual mechanism by which shear stress up-regulates HO-1 and if CORMs can inhibit platelet aggregation in vivo.

2.5.4 CO-Related Angiogenesis

Vascular endothelial growth factor (VEGF) is a potent stimulator of angiogenesis (Miller et al. 2009). Exposure to CO gas or CORMs increased the expression of VEGF in VSMCs (Dulak et al. 2002), human microvascular endothelial cells (Józkowicz et al. 2004; Li Volti et al. 2005), human umbilical vein endothelial cells (HUVECs) (Li Volti et al. 2005), rat primary cardiomyocytes, and H9C2 myocytes (Choi et al. 2010). This mechanism of action was shown to occur through a p38 kinase-dependent pathway (Choi et al. 2010) or phosphatidylinositol 3-kinase (PI3 K)/Akt/mammalian target of rapamycin and MEK/ERK-dependent pathways (Li Volti et al. 2005). As such CORM-2 (Li Volti et al. 2005), -1, and -3 (Józkowicz et al. 2004) were shown to be potent stimulators of angiogenesis. Additionally, methylene chloride (CO-donor; single dose 500 mg/kg) promoted angiogenesis in the infarct heart through the induction of VEGF-B and hypoxia-inducible factor (HIF)-1 α , thus speeding up cardiac repair (Lin et al. 2011).

2.5.5 Anti-Inflammatory Effects of CO

The anti-inflammatory properties of CO and CORMs are partially due to the activation of the signal transduction pathways, such as p38 MAPK (Lakkisto et al. 2010; Ryter and Choi 2007; Otterbein et al. 2000), HIF-1 α (Otterbein et al. 2005; Nakao et al. 2011), peroxisome proliferator-activated receptor- γ (PPAR γ) (Chin et al. 2007; Tsoyi et al. 2009), GC signaling (Nizamutdinova et al. 2009), and CCAATT-enhancer-binding protein (C/EBP)- β/δ (Freitas et al. 2006). Due to its ability to regulate these important pathways or through direct interaction, CO was shown to suppress the activation of pro-inflammatory enzymes, such as inducible NO synthase (iNOS) (Chin et al. 2007; Suh et al. 2006; Oh et al. 2006) and cyclooxygenase-2 (Freitas et al. 2006; Dijkstra et al. 2004), as well as inflammatory transcription factor NF- κ B (Suh et al. 2006; Oh et al. 2006; Dijkstra et al. 2004; Ferrándiz et al. 2008; Cepinskas et al. 2008). As such, CO was shown to inhibit the production of pro-inflammatory cytokines, including macrophage inflammatory protein-1, prostaglandin-2, IL-1 β , -2, -6, -10, and intercellular adhesion molecule (ICAM)-1 (Ryter and Choi 2007; Tsoyi et al. 2009; Freitas et al. 2006; Oh et al. 2006; Dijkstra et al. 2004; Ferrándiz et al. 2008; Cepinskas et al. 2008; Wei et al. 2010), as well as and the expression of toll-like receptor (TLR)-3, -4 (Otterbein et al. 2000; Wei et al. 2010) in macrophages (Ryter and Choi 2007; Otterbein et al. 2000; Freitas et al. 2006; Suh et al. 2006), T cells (Rémy et al. 2009), colonic epithelial cells (Oh et al. 2006), alveolar epithelial cells (Ferrándiz et al. 2008), dendritic cells (Wei et al. 2010), HUVECs (Tsoyi et al. 2009; Ferrándiz et al. 2008), or in joint tissues of a collagen-induced arthritis model (Dijkstra et al. 2004). Needless to say, CO or CORMs administration was shown to decrease leukocyte rolling, adhesion and neutrophil migration into the inflammatory sites

(Nizamutdinova et al. 2009; Pae et al. 2004), and lipopolysaccharide (LPS)-stimulated activation of macrophages (Urquhart et al. 2007; Fujita et al. 2001) and HUVECs (Otterbein et al. 1999).

While a large body of evidence suggests CO to be an anti-inflammatory agent in experimental models, it has yet to be shown if the same can be said in humans. In a randomized, double-blinded, placebo-controlled, two-way cross over clinical trial, inhalation of CO (500 ppm for 1 h) had no anti-inflammatory effect, as measured by cytokine production (TNF- α , IL-1 α/β , -6, -8), against an LPS infusion (Otterbein et al. 2003).

2.5.6 Cardiac Protection from Tissue Reperfusion Injury

Numerous studies have demonstrated the cytoprotection of CO following vascular injury (Clark et al. 2003; Nakao et al. 2011; Cepinskas et al. 2008; Urquhart et al. 2007; Fujita et al. 2001; Otterbein et al. 1999; Mayr et al. 2005). After an ischemic injury, 10–50 μ M CORM-3 produced a significant recovery in myocardial performance and a marked reduction in cardiac muscle damage and infarct size (Clark et al. 2003). The cardioprotective effects mediated by CORM-3 in cardiac cells and isolated hearts were abolished by 5-hydroxydecanoic acid, an inhibitor of mitochondrial ATP-dependent potassium channels (Clark et al. 2003). These authors also found that using a model of cardiac allograft rejection in mice, CORM-3 considerably prolonged the survival rate of transplanted hearts. Recently, it was shown that CORM-2 (8 mg/kg) protected the liver from ischemia–reperfusion injury by up-regulating the expression of the anti-apoptotic protein Bcl-2, down-regulating caspase-3 activation, as well as reducing cellular apoptosis after ischemia–reperfusion injury (Cepinskas et al. 2008). Lastly, CO protected against ischemia–reperfusion injury by inhibiting L-type Ca^{2+} channel mediated influx of Ca^{2+} , which prevented Ca^{2+} overloading and calpain activation; thereby, reducing cellular energy demand required for contraction and preventing ischemic death in H9c2 cells (a rat heart cell line) (Sato et al. 2001).

2.6 Pathophysiological Changes of CO Functions and Metabolism

The lungs are the only site of CO elimination. Exhaled CO is reflective on total blood CO (via carboxyhemoglobin content), due to the equilibrium of CO between the alveolar-capillary barrier in the lungs and blood (Uemura et al. 2005; Kharitonov and Barnes 2001). In fact, the amount of CO exhaled in the breath may correlate to the severity of diabetes (Paredi et al. 1999) and asthma (Jones et al. 1958). Recently, it was reported that individuals who exhaled high levels of CO

were more likely to develop metabolic syndrome and cardiovascular disease events; thus, underscoring the importance of CO in the pathogenesis of metabolic and vascular risk (Cheng et al. 2010).

2.6.1 Diabetes

Diabetes is a disease characterized by chronic high blood sugar levels, where type 1 diabetes is classified as insulin-dependent and type 2 diabetes as non-insulin-dependent diabetes. Interestingly, exhaled CO levels were shown to be significantly increased in diabetic patients (Paredi et al. 1999; Yamaya et al. 2001). Paredi et al. (1999) found that exhaled CO levels were elevated in patients with type 1 and type 2 diabetes up to 4.0 and 5.0 ppm, respectively, compared to healthy subjects (2.9 ppm). Indeed, the authors observed a positive correlation between exhaled CO levels and the incidence of glycemia in all subjects and the duration of the disease (Paredi et al. 1999). An oral glucose tolerance test performed in healthy non-smoking volunteers demonstrated a correlation in plasma glucose levels (3.9–5.5 mM) and exhaled CO (3.0–6.3 ppm), which returned to normal after 40 min of glucose administration (Paredi et al. 1999).

To possibly explain the correlation between CO and glucose levels, Lundquist and associates (Nikberg et al. 1972) showed that glucose stimulated HO activity in intact mouse islets. Interestingly, HO-2 is strongly expressed in both insulin and glucagon secreting cells in the mouse (Nikberg et al. 1972) and in the rat endocrine pancreas (Nikberg et al. 1972). In fact, Goto-Kakizaki rats (a model with defective pancreatic β -cell HO-2) exhibited reduced CO and insulin insufficiency, suggesting that HO-2 plays a critical role in insulin release and glucose metabolism (Henningsson et al. 1999). Studies have shown both hemin and exogenous CO enhanced insulin secretion from glucose-stimulated islets through a GC-dependent pathway (Nikberg et al. 1972; Mosén et al. 2004). Exogenous CO also induced the release of glucagon, which was abrogated by GC inhibition (Nikberg et al. 1972). These studies show that the HO/CO pathway constitutes a novel regulatory system in the stimulation of insulin and glucagon release, and that acute raises in CO may act as a counter-regulatory mechanism in response to increased plasma glucose levels.

On the contrary, studies have shown that HO-1 activity is reduced in aorta and kidney tissues in the Zucker diabetic fatty (ZDF) rats (Mosén et al. 2006; Nicolai et al. 2009) and in aorta extracts from streptozotocin (STZ)-induced rats (Kruger et al. 2006). In fact, CO release from aorta extracts was significantly lower in ZDF rats compared to Zucker lean rats, suggesting that HO-1 activity is inhibited under obese/hyperglycemic conditions (Mosén et al. 2006). Administration of cobalt protoporphyrin (CoPP), an inducer of HO-1 activity, increased CO production in ZDF rats and STZ-induced rats. CoPP-treated ZDF rats showed improved insulin sensitivity, hyperinsulinemia, remodelled adipose tissue, and reduced inflammatory cytokines (Mosén et al. 2006). These metabolic improvements were likely due to increased phosphorylation of Akt and AMP-activated protein kinase (AMPK) in

the aorta and kidney, as well as serum adiponectin (Mosén et al. 2006). Studies have shown that activation of AMPK and p-Akt increases glucose transport, fatty acid oxidation (Di Pascoli et al. 2006; Kurth-Kraczek et al. 1999) and phosphorylated endothelial nitric oxide synthase (eNOS) (Stoppani et al. 2002). However, it is not clear whether enhanced CO, not biliverdin or released Fe^{II} , is the main contributor to the significant metabolic improvements observed in CoPP-treated ZDF rats. Further research is needed to identify the source response for the increased exhaled CO levels in diabetic patients and if exhaled CO can be used as a prognostic factor in the development of and monitoring diabetes.

Interestingly, STZ-treated rats exhibited reduced sensitivity to CO-induced vasorelaxation compared to normal rats (Dimmeler et al. 1999). The decreased vasorelaxant effect of CO was related to diminished sensitivity of BK_{Ca} channels in VSMCs due to hyperglycemia-induced glycation (Dimmeler et al. 1999). This constitutes a novel mechanism for the diabetic vascular complications.

2.6.2 Vascular Proliferative Diseases

The hallmark of vascular proliferative diseases includes VSMC hypertrophy and hyperplasia due to severe imbalance in the redox homeostatic signaling of cellular proliferation and apoptosis. CO was shown to prevent intimal hyperplasia by arresting hyperproliferative VSMCs (Otterbein et al. 2003, 2005; Wang et al. 2001; Raman et al. 2006), increase mobilization, and recruitment of bone-marrow-derived progenitor cells to denuded vessels, as well as enhance re-endothelialization due to its pro-proliferative actions on endothelial cells (Otterbein et al. 2005; Ramlawi et al. 2007). The later is said to be dependent upon NOS and NO, involving the modulation of RhoA and Akt (Ramlawi et al. 2007) or HIF-1 α /VEGF (Otterbein et al. 2005) signaling pathways and may help prevent restenosis.

2.6.2.1 Hypertension

Chronic hypertension is characterized by vascular structural changes, such as vessel wall hypertrophy and hyperplasia, which contributes to elevated resistance and high blood pressure (Wegiel et al. 2010). HO-1 is pathophysiologically activated by hemodynamic stress in response to elevated blood pressure, where the expression and activity of HO-1, sGC, and cGMP in VSMCs are associated with different stages of hypertension development (Wegiel et al. 2010). Kobayashi et al. (2007) and Ndisang et al. (2004) demonstrated that inhaled CO (60 ppm) significantly decreased left ventricular hypertrophy and aortic hypertrophy, which attenuated the development of angiotension II-dependent hypertension in mice. These cytoprotective mechanisms of CO were due to reduced ROS production via the reduction of Nox and Akt phosphorylation (Ndisang et al. 2004). Furthermore, both CoPP and CORM-3 (2 mg/100 g) increased the dilatory response to acetylcholine (ACh) in Sprague–Dawley rats,

which was likely due to a CO-induced decrease in iNOS expression leading to improved vascular reactivity (Kruger et al. 2006).

Pulmonary arterial hypertension (PAH) is characterized by vascular proliferation and remodeling in the small pulmonary arteries, which leads to a progressive increase in pulmonary vascular resistance, eventually resulting in right heart failure. Exposure to inhaled CO (250 ppm, 1 h/day for 2 or 3 weeks) reversed established PAH and right ventricular hypertrophy, restored right ventricular and pulmonary arterial pressures, as well as pulmonary vascular architecture in mice (Kobayashi et al. 2007). The mechanism of action was dependent upon CO-induced up-regulation of eNOS and NO generation, as well as stimulated apoptosis and inhibition of cell proliferation in VSMCs (Kobayashi et al. 2007). In fact, the HO/CO system seems to attenuate hypertension only when the NOS pathway is fully operative (Zuckerbraun et al. 2006). Additionally, Dubuis et al. (2005) demonstrated that chronic CO inhalation (50 ppm for 21 days) attenuated hypoxic PAH development, likely through BK_{Ca} channel activation.

Hemin supplementation has been used extensively to up-regulate the HO-1/CO system and has shown success in the treatment of hypertension (Polizio et al. 2011; Ndisang et al. 2002; Ndisang et al. 2003; Shamloul and Wang 2005; Wang et al. 2006). Interestingly, hemin therapy was shown to lower blood pressure in young spontaneously hypertensive rats (SHRs) (8 weeks), but not in adult SHRs (20 weeks). Indeed, a desensitized HO/CO-sGC/cGMP system may take the blame in mesenteric artery (Polizio et al. 2011) and aortic tissues (Ndisang et al. 2002) of adult SHRs; leading to treatment failure. Young SHRs have a defective, yet responsive, HO/CO-sGC/cGMP system, where hemin supplementation was shown to normalize high blood pressure (Polizio et al. 2011; Ndisang et al. 2002). Intriguingly, chronic hemin treatment (15 mg/kg per day for 21 days) established long-lasting antihypertension protection for 9 months after the removal of implanted hemin osmotic minipumps in 12-week-old SHRs (Shamloul and Wang 2005). Additionally, this hemin protocol reversed SHR-featured arterial eutrophic inward remodeling and decreased expression levels of vascular endothelial growth factor in SHRs (Shamloul and Wang 2005). The sustained up-regulation of HO-1 expression in vascular tissues and normalization of blood pressure of SHRs may have been due to residual hemin accumulation within VSMCs. As such, Chang et al. (2008) showed that hemin treatment (5 μ M for 21 days) contributed to vascular remodeling by inhibiting proliferation of cultured rat aortic VSMCs by arresting cells at G0/G1 phases (Wang et al. 2006). Hemin treatment also decreased the expression of p21 protein (an important negative regulator for cell proliferation) and the level of ROS (Wang et al. 2006). Overall, application of this hemin technology at physiologically or therapeutically relevant concentrations will pave the way for novel and long-lasting treatment regimens for hypertension.

The transient up-regulation of HO-1 may represent the first line of defence in the pathophysiological development of hypertension. However, the protective effects of the HO/CO system in hypertension are not without controversy. For instance, in Dahl salt-sensitive rats, vascular reactivity to ACh was restored immediately upon inhibition of HO (Chang et al. 2008). In agreement, HO inhibition improved

ACh-induced vasodilation and lowered systolic blood pressure in obese Zucker rats (Johnson et al. 2003). This suggests that CO overproduction in the vasculature induces endothelial dysfunction, leading to hypertension.

2.6.2.2 Atherosclerosis

Atherosclerosis is a multifacet disease involving endothelial dysfunction, inflammation, and vascular proliferation. Considerable evidence suggests that HO-1 is up-regulated and plays a beneficial role against atherosclerosis development [for review, see (Johnson et al. 2006)]; however, less is known about the direct effects of CO signaling in atherosclerosis.

CO may serve as a strong anti-atherosclerotic agent due to its VSMCs apoptotic properties, induction on endothelial cell proliferation, and anti-inflammatory effects. Indeed, exposure to CO (250 ppm; 1 h before vascular injury) blocked the development of arteriosclerotic lesions associated with chronic graft rejection and balloon angioplasty-induced vessel injury in rats (Wang et al. 2001). The protective effect of CO is mainly attributed on its ability to suppressing intimal hyperplasia arising from balloon injury, as well as blocking leukocyte infiltration/activation and VSMC proliferation (Wang et al. 2001). Recently, it was shown that the reciprocal relationship between the HO-1/CO and NOS/NO systems plays an inhibitory role in atherosclerotic plaque formation (Durante 2011). It has also been reported that CO-induced VSMC proliferation inhibition is dependent on the GC/cGMP and p38 MAPK signaling pathways (Wang et al. 2001) and the down-regulation of endothelin-1 (a mediator known to induce VSMC proliferation) (Durante 2011).

2.6.3 Myocardial Infarction

CO can also contribute protective actions in the heart. CORM-3 treatment was shown to reduce cardiac muscle damage and infarct size, as well as preserve cell viability and myocardial performance against hyperoxia-reoxygenation damage in isolated cardiac cells or hearts (Clark et al. 2003; Liu et al. 2010), mimicking the late phase of ischemic preconditioning (Guo et al. 2004). Pre-exposure to inhaled CO gas (1,000 ppm) prior to myocardial ischemia-reperfusion injury reduced infarct area and suppressed the migration of macrophages and monocytes into the infarcted zone in rats (Stein et al. 2005). The cardioprotective effects of CO on cardiac ischemia-reperfusion injury seemed to be mediated by the p38 MAPK and Akt-eNOS pathways, including cGMP production (Stein et al. 2005). Likewise, another study demonstrated that CO (250 ppm) inhalation improved cardiac energetics and protected the heart during reperfusion after cardiopulmonary bypass in pigs (Fujimoto et al. 2004) and attenuated ischemia-reperfusion injury in mice due to its anti-apoptotic action (Lavitrano et al. 2004). Additionally, Lakkisto et al.

(2010) and Lin et al. (2011) demonstrated that methylene chloride (500 mg/kg) promoted cardiac repair in the infarct heart by inducing angiogenesis and cardiomyocyte proliferation in the infarct border area.

2.7 The Cellular and Molecular Mechanisms of CO Effects

CO has a strong affinity for metal atoms; specifically iron in the reduced state, thereby allowing CO to exclusively react with a number of metalloproteins, such as hemoglobin, sGC, COX, cytochrome p450, cytochrome *c* oxidase, NOS, and Nox (Estabrook et al. 1970; Akamatsu et al. 2004; Roberts et al. 2004; Boczkowski et al. 2006; Dioum et al. 2002; Ryter and Otterbein 2004). To a weaker extent, CO can interact with non-metal containing molecules, such as amino acids and lipids (Ryter and Otterbein 2004). Although weak, these interactions can trigger a biochemical change in the structure of these proteins, thus altering their function and likely signaling cascades.

2.7.1 CO-Induced ROS Production

Low concentrations of ROS act as important second messengers to modulate intracellular signaling pathways generation (Bilban et al. 2008) by affecting the activity, as well as protein–protein and protein–DNA interaction of enzymes and transcription factors (Finkel and Holbrook 2000). CO can modulate cellular ROS generation, such as superoxide anion (O_2^-) and hydrogen peroxide (H_2O_2) from mitochondria-dependent and cytosolic sources. Regulation of ROS production is the main mechanism by which CO alters major cell signaling pathways. This includes the phosphorylation of Akt (Kim et al. 2008; Finkel 1998), activation of NF- κ B (Kim et al. 2008), p38 MAPK (Kobayashi et al. 2007), Bax and Bid (Suliman et al. 2007), up-regulation of PPAR γ (Wang et al. 2007), HIF-1 α and TGF- β (Nakao et al. 2011), secretion of TNF- α , as well as inhibition of ERK-1/2 and cyclin D1 expression (Bilban et al. 2006), mitochondrial cytochrome *c* release (Suliman et al. 2007), and TLR-2, -4, -5, and -9 signaling (Taillé et al. 2005).

The electron transport chain (ETC) is the major site of ATP production in the mitochondria, which heavily relies on oxygen to power the electron cycle (Bilban et al. 2008). The ETC is also the major for ROS production, including O_2^- and H_2O_2 (Bilban et al. 2008). CO interferes with the ETC by binding to cytochrome *c* oxidase for oxygen, thus modulating the enzyme's catalytic activity (Nakahira et al. 2006; Lo Iacono et al. 2011; Alonso et al. 2003). Cytochrome *c* oxidase is located within Complex IV and is the terminal enzyme of the ETC. CO also binds to cytochrome P450 thus directly inhibiting Complex IV (Brown and Piantadosi 1990; Frolkis et al. 2003). As a result, CO promotes electron leakage from the ETC leading to an induction in ROS production. Interestingly, CO was also shown to inhibit Nox, thus leading to the subsequent down-regulation of O_2^- production (Suliman et al. 2007;




Fig. 2.2 CO regulation of important ion channels in the cardiovascular system

Bilban et al. 2006; Taillé et al. 2005). However, the affinity of CO to Nox is weak, and thus the reaction is slow (Piantadosi 2008; Nisimoto et al. 1994). Nonetheless, ROS production and signaling by Nox is decreased, but there is a simultaneous increase in ROS production from the mitochondria (Bilban et al. 2006).

The transient increase in CO-induced ROS production is likely responsible for the protective induction of antioxidant enzymes and protective genes, because it forces the cell to undergo an oxidative conditioning to attenuate further ROS production (Finkel 1998; Lutter et al. 1985). CO was shown to have antioxidant properties, because it reduced hepatic lipid peroxidation, re-established total hepatic glutathione and glutathione disulfide levels and protected HUVECs against TNF- α -induced oxidative stress (Lutter et al. 1985). Yet, chronic exposure to CO (30 ppm/day plus five 1 h peaks at 100 ppm, 4 weeks) promotes oxidative stress in rats (Brugger et al. 2010). Thus, it seems the cytoprotective effects of CO signaling are dependent on exposure duration and CO concentration.

2.7.2 Ion Channel Signaling

Crucial to the role of CO in physiology and disease is its ability to regulate several classes of ion channels. These include BK_{Ca}, Ca²⁺ channel (L-type) families, ligand-gated P2X receptors (P2X2 and P2X4), and the epithelial Na⁺ channel (ENaC). These important ion channel targets of CO are summarized in Fig. 2.2.

2.7.2.1 BK_{Ca}

Opening of BK_{Ca} channels leads to hyperpolarization, which closes the voltage-dependent Ca²⁺ channels, reduces intracellular Ca²⁺ concentrations, leading to vascular relaxation. BK_{Ca} are by far the most studied ion channel target of CO. CO signaling was shown to mediate the activation of BK_{Ca} in systemic arterial smooth muscle (André et al. 2011; Wu et al. 2002; Wang and Wu 1997; Wang et al. 1997), oxygen-sensitive glomus cells of the carotid body (Wang et al. 1997; Riesco-Fagundo et al. 2001), pulmonary artery myocytes (Dubuis et al. 2005), and in venous endothelial cells (Williams et al. 2004).

The conductance and opening probability of BK_{Ca} channels are determined by specific amino acid residues that compose the channel protein. Wang et al. (1997), Wu et al. (2002), Wang and Wu (1997) showed that CO increased the opening probability, but not the conductance, of BK_{Ca} channels, suggesting that the gating mechanism is likely modified by CO. Administration of diethyl pyrocarbonate, a chemical that reacts only with the unprotonated imidazole ring of histidine, abolished the effect of CO on BK_{Ca} channels, which was restored upon removal of diethyl pyrocarbonate (Wu et al. 2002). Additionally, photo-oxidation with rose Bengal, which modifies only histidine residues located on the external surface of the cell membrane, also blocked the stimulatory effect of CO on BK_{Ca} channels (Wu et al. 2002). These observations suggest that an interaction between CO and the imidazole group of an extracellular histidine residue could be largely responsible for CO-induced BK_{Ca} channel activation in rat VSMCs (Wu et al. 2002).

A site-directed mutagenesis of a cysteine residue at position 911 in the intracellular C-terminal domain significantly reduced, but not completely, the ability of CO to activate human BK_{Ca} channel subunit (Dong et al. 2007). Another study showed that mutations of histidine 365, histidine 394, and aspartate 367 (amino acid residues located in the cytoplasmic high-affinity divalent cation sensor in the RCK1 domain) appear to alter CO affinity to BK_{Ca} channels (Telezhkin et al. 2011). Therefore, it is possible that these residues (Telezhkin et al. 2011), the extracellular histidine residue (Wu et al. 2002), and the C911 residue (Dong et al. 2007) all contribute to the site of action of CO. Furthermore, different subtypes of BK_{Ca} channels are expressed in different types of cells from different species. This would also explain the aforementioned reports.

Intriguingly, the stimulatory effects of CO and NO on BK_{Ca} activation may have different molecular basis in regards to their unique molecular and functional interactions with the channel subunits. Wu et al. (2002) and André et al. (2011) demonstrated that NO activated BK_{Ca} channels by interacting with the BK_{Ca}, β 1 subunit, whereas CO stimulated channel opening via the BK_{Ca}, α subunit in rat VSMCs. Moreover, NO has a stronger potency for BK_{Ca} activation compared to CO, and pre-treatment of NO abolished CO-induced activation of the BK_{Ca} channels (André et al. 2011). Indeed, NO binding to the BK_{Ca}, β 1 subunit may exert an allosteric effect on the neighboring BK_{Ca}, α subunit, thus suggesting a feedback mechanism between NO and CO signaling in order to regulate vascular contractility (André et al. 2011).

2.7.2.2 Ca^{2+} Channel (L-Type) Receptors

CO regulation of L-type Ca^{2+} channels is controversial. CORM-2 or CO inhibits cardiac L-type channel ($\alpha_1\text{C}$ or CACNA1C) in native rat cardiomyocytes (Hou et al. 2008), HEK293 cells (Hou et al. 2008; Scragg et al. 2008), or in H9c2 cells (a rat heart cell line) (Sato et al. 2001). CO inhibits channel activation via the transient increase in mitochondrial ROS formation, leading to the modulation of three specific cysteine residues (at positions 1789, 1790, and 1810) in the C-terminal tail of L-type Ca^{2+} channel (Hou et al. 2008). In stark contrast, CO was shown to activate L-type Ca^{2+} channels in human recombinant intestinal smooth muscle cells (Dallas et al. 2009). In fact, CO induces channel activation through a NO-dependent mechanism (Dallas et al. 2009). These contradicting observations may be due to differences in the cellular redox state or tissue-specific splice variation, which was also observed in oxygen regulation of L-type channels (Lim et al. 2005; Wilkinson and Kemp 2011a).

2.7.2.3 Ligand-Gated P2X Receptors

P2X receptors are ligand-gated ion channels that are opened by the binding of extracellular ATP (Fearon et al. 2000). P2X receptors initiate contraction in cardiomyocytes and in various smooth muscle cells, and are the only ligand-gated ion channel to be modulated by CO (Fearon et al. 2000; Alexander et al. 2008). CORM-2 enhances ATP-evoked P2X2 currents in rat pheochromocytoma cells, but inhibits currents evoked by P2X2/3 and P2X4 receptors in the presence of high ATP in HEK293 cells (Wilkinson and Kemp 2011a, b). Recently, it was shown that CORM-2 inhibited human recombinant P2X4 channels in HEK293 cells (Wilkinson et al. 2009). CO likely regulates P2X channels through a cGMP-independent pathway (Wilkinson and Kemp 2011a, b; Wilkinson et al. 2009) and mitochondrial-ROS generation (Wilkinson et al. 2009).

2.7.2.4 ENaC

ENaC plays an important role in reabsorption of sodium primarily in the kidney, colon, and lung (Fearon et al. 2000). CO regulation of ENaC is also controversial. For instance, CORM-2 activates ENaC in inside-out membrane patches in a kidney cortical collecting duct cell line (Wilkinson and Kemp 2011a, b); yet, CORM-3 inhibits ENaC in rat cultured alveolar type II cells and in a human airway cell line (Wang et al. 2009). The latter occurs through a diethyl pyrocarbonate-dependent mechanism, which is dependent upon important histidine residues (Wang et al. 2009). These divergent results may reflect tissue-specific differences in ENaC subunit composition, species variation in amino acid sequences, and experimental methodology.

2.7.3 CO-Induced Activation of Major Signaling Pathways

2.7.3.1 MAPK

Numerous studies have linked the p38 MAPK pathway to the anti-inflammatory, anti-apoptotic, and antiproliferative effects of CO (Brouard et al. 2000; Ryter and Choi 2007; Otterbein et al. 1999; Lutter et al. 1985; Althaus et al. 2009). MAPK is a non-metal protein that plays a critical role in cellular signal transduction, where all three MAPK members (Jun-activated kinases; JNK, p38 and ERK) may be involved in proliferation and cell-cycle progression (Bergstraesser et al. 2011). In fact, CO signaling was shown to inhibit the induction of ERK1/2 in human airway smooth muscle cells (Song et al. 2002; Bilban et al. 2006), in the rat kidney (Cargnello and Roux 2011), and rat lung (Nakao et al. 2009), as well as induce JNK-1 and -2 activation in rat aorta tissues (Wang et al. 2001).

The p38 isoforms (α , β , γ , and δ) are broadly sensitive to oxidative, environmental, and inflammatory stress and are thus up-regulated in response to these stressors (Bergstraesser et al. 2011). Therefore, CO likely up-regulates p38 MAPK primarily through the transient burst of ROS (Bilban et al. 2006). CO was also shown to up-regulate p38 MAPK through the cGMP/GC pathway (Wang et al. 2001). Interestingly, CO (250 ppm) up-regulated p38, specifically p38 β and down-regulated p38 α expression, which mediated CO-induced cytoprotection against hyperoxic stress in human alveolar epithelial cells (Otterbein et al. 1999). However, in the same cell line, CORM-3 (1 mM) inhibited the expression of p38 (Althaus et al. 2009). This controversy may be due to the physical form of CO (CO gas vs. CORM-3), the concentration (250 ppm vs. 1 mM), and the experimental conditions (hyperoxic vs. TNF- α -stimulation). Also, it is not clear in which p38 isoform CO regulated in the later study (Althaus et al. 2009).

2.7.3.2 PI3K-Akt

PI3K/Akt signaling is involved in pro-survival signaling, glucose metabolism, and cell proliferation (Mishra et al. 2006). CO signaling was shown to induce Akt expression in rat endothelial cells (Cantley 2002), isolated mouse cardiomyocytes (Finkel 1998), rat hepatocytes (Kim et al. 2008), and rat hearts (Stein et al. 2005). The mechanism of action by which CO activates Akt is through CO-induced mitochondrial H₂O₂ production. Excess H₂O₂ oxidizes the functional thiol groups on counter-regulatory phosphatase like phosphatase and tensin homologs and protein-tyrosine phosphatase-1B, leading to their inactivation (Zhang et al. 2005; Lee et al. 2002). The inactivation of these phosphatase permits unopposed activity of Akt. Induction of Akt, observed after CO treatment, leads to oxidative phosphorylation, heme synthesis, and mitochondrial biogenesis (Finkel 1998), angiogenesis by HIF-1 α stabilization (Li Volti et al. 2005), as well as cell survival (Kim et al. 2008; Stein et al. 2005; Cantley 2002).

2.7.3.3 STAT

The signal transducers and activators of the transcription (STAT) family of transcription factors mediate cytokine- and growth factor-induced signals that regulate cellular proliferation and differentiation (Leslie et al. 2003). STAT3 was shown to up-regulate manganese superoxide dismutase (Battle and Frank 2002) and molecules essential for cell growth and survival, such as heat-shock proteins and growth factors (Negoro et al. 2001; Kunisada et al. 2000). CO can differentially modulate STAT1 and STAT3 activation, where STAT3 activation by CO is responsible for the anti-apoptotic effect in endothelial cells during anoxia-reoxygenation injury (Cantley 2002). Additionally, it was shown that endothelial STAT3 is essential for the protective effects of CO in oxidant-induced lung injury and cell death (Stephanou and Latchman 1999). Likewise, exogenous CO was unable to fully block hyperoxia-induced apoptosis in STAT3-deficient mice or in lung endothelial cells transfected with STAT3 siRNA (Stephanou and Latchman 1999).

2.7.3.4 PPAR

PPARs play essential roles in adipogenesis and glucose homeostasis, and negatively regulate inflammatory responses (Zhang et al. 2006). So far, three PPAR isoforms have been identified, PPAR α , PPAR β/δ , and PPAR γ . Numerous studies report the induction of PPAR γ with CO treatment (Chin et al. 2007; Tsoyi et al. 2009; Wang et al. 2007; Ricote et al. 1998; Haschemi et al. 2011; Hoetzel et al. 2008). Recently, it was demonstrated that exogenous CO enhanced SUMOylation of PPAR γ in LPS-treated macrophages via mitochondrial ROS production (Ricote et al. 1998). SUMOylation is a protein modification that has significant bearing on inflammatory responses (Ricote et al. 1998). Through the induction of PPAR γ , CORM-2 was shown to down-regulate iNOS in LPS-activated macrophages (Chin et al. 2007) and inhibit high-glucose-induced ICAM expression in HUVECs (Tsoyi et al. 2009), thus reducing the inflammatory state. Inhaled CO was also shown to protect against ventilator-induced lung injury via PPAR γ activation (Haschemi et al. 2011).

2.7.3.5 HIF-1 α

HIF-1 α is an oxygen sensor and a transcriptional complex involved in the regulation of cell survival, angiogenesis, glucose metabolism, and inflammation (Woo et al. 2006). CO was reported to increase the stability of HIF-1 α in macrophages (Nakao et al. 2011), endothelial cells (Li Volti et al. 2005), vein grafts from the inferior vena cava (LE Otterbein et al. 2005), and in cardiomyocytes (Lin et al. 2011). CO-induced HIF-1 α expression is necessary to prevent anoxia/reoxygenation-induced apoptosis, preserve cellular homeostasis at the site of injury (Nakao et al. 2011), and promote cardiac regeneration in a myocardial infarct model (Lin et al. 2011). It was demonstrated that CORM-2 increased the stability of the HIF-1 α protein by suppressing

its ubiquitination and increasing HIF-1 α /HSP90 α interaction, which is responsible for HIF-1 α stabilization (Li Volti et al. 2005). Lastly, ex vivo CO treatment of vein grafts resulted in increased HIF-1 α activation in the vein grafts, thus preventing intimal hyperplasia (LE Otterbein et al. 2005).

On the contrary, one study showed that CO (10–80 %) suppressed the activation of HIF-1 α by triggering destabilization of HIF-1 α in Hep3B cells under hypoxia conditions (Semenza 2007). However, the authors of this study used high concentrations of CO since CO has a low affinity for direct HIF-1 α binding (Semenza 2007), whereas others have shown that low concentrations of CO induced HIF-1 α activation, indirectly, likely through the PI3K/Akt and MAPK pathways (Li Volti et al. 2005) or mitochondrial-ROS production (Nakao et al. 2011).


2.7.3.6 sGC

Similar to NO, CO can stimulate sGC leading to an elevation of intracellular cGMP levels. This effect was shown to occur in VSMCs (Ramos et al. 1989), human internal thoracic and radial artery rings (Achouh et al. 2008), and in the liver (Suematsu et al. 1995). CO binds to the heme moiety of sGC, thus stimulating sGC and elevating intracellular levels of cGMP leading to vasorelaxation (Ramos et al. 1989; Achouh et al. 2008; Suematsu et al. 1995), anti-inflammation (Nizamutdinova et al. 2009), inhibition of anti-platelet activation (Brüne and Ullrich 1987), and regulation of glucose metabolism (Nikberg et al. 1972; Mosén et al. 2004). Interestingly, studies have shown that NO is about 30–100-fold (Huang et al. 1999) more potent than CO in stimulating sGC in vitro (Furchgott and Jothianandan 1991; Lee et al. 2000) and NO-induced vasorelaxation is about 1000-fold greater than CO-mediated vasodilation (Huang et al. 1999). However, Zakhary et al. (1997) and Stone and Marletta (1994) demonstrated that intestinal cGMP levels were depleted in HO-2 knockout mice to the same extent as nNOS knockout mice.

2.8 The Interaction of CO with NO and H₂S

It is abundantly clear that CO, NO, and H₂S interact amongst themselves (Fig. 2.3). NO up-regulates HO-1 expression thus enhances the generation of endogenous CO (Zakhary et al. 1997; Amersi et al. 1999; Motterlini et al. 2002). In fact, NO is the one of the most potent inducers of HO-1 (Foresti and Motterlini 1999; Motterlini et al. 2002). In turn, CO attenuates iNOS activity by binding to the heme moiety of the enzyme (Polte et al. 2000; Kim et al. 2008; Lin et al. 2003) and mediates iNOS protein expression levels through p38 (Motterlini et al. 2002) and protein turnover (Polte et al. 2000; Datta et al. 2002; Foresti et al. 2003). Taking this interrelationship into account, it has been suggested that CO regulates iNOS expression and activity in order to modulate the tissue stress response (Motterlini et al. 2002; Datta et al. 2002; Foresti et al. 2003; Motterlini et al. 1997).

Fig. 2.3 Interrelationship between CO, NO, and H₂S



In other words, CO could act as a feedback inhibitor of iNOS when NO concentrations exceed the homeostatic threshold (Sawle et al. 2005). Indeed, NO derived from iNOS induces HO-1 expression (Turcanu et al. 1998) and potentiates HO-1 induction (Vicente et al. 2001), whereby HO-1 activity inhibits iNOS expression (Sawle et al. 2005). On the contrary, CO was shown to increase iNOS protein expression following TNF- α /D-galactosamine treatment in mice, which resulted in liver protection (Naughton et al. 2002). How CO differently regulates iNOS expression in different organs or different stimuli is not clear.

Interaction of CO with H₂S is another interesting signaling event. One report showed that H₂S administered to rats with hypoxia pulmonary hypertension increased plasma CO concentration and HO-1 expression in the pulmonary artery (Qingyou et al. 2004). In fact, when rats were given DL-propargylglycine (an inhibitor of cystathionine γ -lyase) to inhibit endogenous H₂S production, HO-1 gene and protein expression were significantly reduced, and consequently, plasma CO concentration (Qingyou et al. 2004). The mechanism by which H₂S up-regulates the HO-1/CO system is not fully understood; however, hemoglobin, the common “sink” may have been involved in the displacement of CO in the presence of high H₂S, thereby increasing the release of CO. In agreement, another group showed that H₂S up-regulates HO-1 expression, via ERK activation, in LPS-stimulated macrophages (Suh et al. 2006). H₂S-induced up-regulation of HO-1 resulted in the down-regulation of iNOS/NO system and NF- κ B activation (Oh et al. 2006). Other indirect evidence shows that H₂S inhibits all three NOS isoforms (eNOS, iNOS, and neural NOS) (Kubo et al. 2007), thus suggesting an interference in the NOS/NO-induced up-regulation of the HO-1/CO system. We have only begun to scratch the surface of the complex interrelationship of CO with NO and H₂S. This field of research holds exciting prospects related to gasotransmitter interactions.

2.9 Perspectives

CO has come a long way from solely being considered an environmental pollutant to an important gasotransmitter involved in a number of physiological processes in both physiological and pathophysiological systems. Toxicology studies are needed

to establish the safety profile of prolonged exposure to various CO concentrations in pre-clinical studies. The routes for CO administration as a therapeutic agent will require better controlled and designed examination to optimize the absorption, distribution, and the systemic impacts of CO. The next important objective is to validate the therapeutic benefits of CO observed in various animal models in humans. Moreover, the ability to use exhaled CO as a reliable, non-invasive biomarker in diabetes and metabolic syndrome could be promising for gauging disease severity and therapeutic efficacy. Furthering our understanding of the metabolism and function of CO will lead to rational drug design for novel therapeutic gain in preventing and treating different diseases.

Acknowledgments This study has been supported by a Discovery Grant from Natural Sciences and Engineering Research Council of Canada

References

- Abraham NG, Kappas A (2008) Pharmacological and clinical aspects of heme oxygenase. *Pharm Rev* 60:79–127. doi:[10.1124/pr.107.07104](https://doi.org/10.1124/pr.107.07104)
- Abraham NG, Jiang H, Balazy M, Goodman AI (2003) Methods for measurements of heme oxygenase (HO) isoforms-mediated synthesis of carbon monoxide and HO-1 and HO-2 proteins. *Methods Mol Med* 86:399–411. doi:[10.1385/1-59259-392-5:399](https://doi.org/10.1385/1-59259-392-5:399)
- Achouh PE, Simonet S, Fabiani JN, Verbeuren TJ (2008) Carbon monoxide induces relaxation of human internal thoracic and radial arterial grafts. *Interact Cardiovasc Thorac Surg* 7:959–962. doi:[10.1510/icvts.2008.180489](https://doi.org/10.1510/icvts.2008.180489)
- Akamatsu Y, Haga M, Tyagi S, Yamashita K, Graca-Souza AV, Ollinger R, Czismadia E, May GA, Ifedigbo E, Otterbein LE, Bach FH, Soares MP (2004) Heme oxygenase-1-derived carbon monoxide protects hearts from transplant associated ischemic reperfusion injury. *FASEB J* 18:771–772. doi:[10.1096/fj.03-0921fje](https://doi.org/10.1096/fj.03-0921fje)
- Alexander SP, Mathie A, Peters JA (2008) Guide to receptors and channels (GRAC), 3rd edn. *Br J Pharmacol* 153:Suppl 2:S1-209. doi:[10.1038/sj.bjp.0707746](https://doi.org/10.1038/sj.bjp.0707746)
- Alonso R, Cardellach F, Lopez S, Casademont J, Miro O (2003) Carbon monoxide specifically inhibits cytochrome c oxidase of human mitochondrial respiratory chain. *Pharmacol Toxicol* 93:142–146. doi:[10.1034/j.1600-0773.2003.930306.x](https://doi.org/10.1034/j.1600-0773.2003.930306.x)
- Althaus M, Fronius M, Buchäcker Y, Vadász I, Clauss WG, Seeger W, Motterlini R, Morty RE (2009) Carbon monoxide rapidly impairs alveolar fluid clearance by inhibiting epithelial sodium channels. *Am J Respir Cell Mol Biol* 41:639–650. doi:[10.1165/rcmb.2008-0458OC](https://doi.org/10.1165/rcmb.2008-0458OC)
- Amersi F, Buelow R, Kato H, Ke B, Coito AJ, Shen XD, Zhao D, Zaky J, Melinek J, Lassman CR, Kolls JK, Alam J, Ritter T, Volk HD, Farmer DG, Ghobrial RM, Busuttil RW, Kupiec-Weglinski JW (1999) Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury. *J Clin Invest* 104:1631–1639. doi:[10.1172/JCI17903](https://doi.org/10.1172/JCI17903)
- André L, Gouzi F, Thireau J, Meyer G, Boissiere J, Delage M, Abdellaoui A, Feillet-Coudray C, Fouret G, Cristol JP, Lacampagne A, Obert P, Reboul C, Fauconnier J, Hayot M, Richard S, Cazorla O (2011) Carbon monoxide exposure enhances arrhythmia after cardiac stress: involvement of oxidative stress. *Basic Res Cardiol* 106:1235–1246. doi:[10.1007/s00395-011-0211-y](https://doi.org/10.1007/s00395-011-0211-y)
- Antuni JD, Kharitonov SA, Hughes D, Hodson ME, Barnes PJ (2000) Increase in exhaled carbon monoxide during exacerbations of cystic fibrosis. *Thorax* 55:138–142. doi:[10.1136/thorax.55.2.138](https://doi.org/10.1136/thorax.55.2.138)
- Barinaga M (1993) Carbon monoxide: killer to brain messenger in one step. *Science* 259:309. doi:[10.1126/science.8093563](https://doi.org/10.1126/science.8093563)

- Battle TE, Frank DA (2002) The role of STATs in apoptosis. *Curr Mol Med* 2:381–392. doi:[10.2174/1566524023362456](https://doi.org/10.2174/1566524023362456)
- Bergstraesser C, Hoeger S, Song H, Ermantraut L, Hottenrot M, Czymai T, Schmidt M, Goebeler M, Ponelies N, Stich C, Loesel R, Molema G, Seelen M, van Son W, Yard BA, Rafat N (2011) Inhibition of VCAM-1 expression in endothelial cells by CORM-3: The role of the ubiquitin-proteasome system, p38, and mitochondrial respiration. *Free Radic Biol Med*. doi:[10.1016/j.freeradbiomed.2011.11.035](https://doi.org/10.1016/j.freeradbiomed.2011.11.035)
- Biernacki WA, Kharitonov SA, Barnes PJ (2001) Exhaled carbon monoxide in patients with lower respiratory tract infection. *Respir Med* 95(12):1003–1005. doi:[10.1053/rmed.2001.1196](https://doi.org/10.1053/rmed.2001.1196)
- Bilban M, Bach F, Otterbein S, Ifedigboe E, deCosta d'Avila J, Esterbauer H, Chin B, Usheva A, Robson S, Wagner O, Otterbein LE (2006) Carbon monoxide orchestrates a protective response through PPARgamma. *Immunity* 24:601–610. doi:[10.1016/j.immuni.2006.03.012](https://doi.org/10.1016/j.immuni.2006.03.012)
- Bilban M, Haschemi A, Wegiel B, Chin BY, Wagner O, Otterbein LE (2008) Heme oxygenase and carbon monoxide initiate homeostatic signaling. *J Mol Med* 86:267–279. doi:[10.1007/s00109-007-0276-0](https://doi.org/10.1007/s00109-007-0276-0)
- Boczkowski J, Poderoso JJ, Motterlini R (2006) CO-metal interaction: vital signaling from a lethal gas. *Trends Biochem Sci* 31:614–621. doi:[10.1016/j.tibs.2006.09.001](https://doi.org/10.1016/j.tibs.2006.09.001)
- Boehning D, Moon C, Sharma S, Hurt KJ, Hester LD, Ronnett GV, Shugar D, Snyder SH (2003) Carbon monoxide neurotransmission activated by CK2 phosphorylation of heme oxygenase-2. *Neuron* 40:129–137. doi:[10.1016/S0896-6273\(03\)00596-8](https://doi.org/10.1016/S0896-6273(03)00596-8)
- Boehning D, Sedaghat L, Sedlak TW, Snyder SH (2004) Heme oxygenase-2 is activated by calcium-calmodulin. *J Biol Chem* 279:30927–30930. doi:[10.1074/jbc.C400222200](https://doi.org/10.1074/jbc.C400222200)
- Botros FT, Navar LG (2006) Interaction between endogenously produced carbon monoxide and nitric oxide in regulation of renal afferent arterioles. *Am J Physiol Heart Circ Physiol* 291:H2772–H2778. doi:[10.1152/ajpheart.00528.2006](https://doi.org/10.1152/ajpheart.00528.2006)
- Brouard S, Otterbein LE, Anrather J, Tobiasch E, Bach FH, Choi AM, Soares MP (2000) Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. *J Exp Med* 192:1015–1026
- Brown D, Piantadosi A (1990) In vivo binding of carbon monoxide to cytochrome c oxidase in rat brain. *J Appl Physiol* 68:604–610
- Brugger J, Schick MA, Brock RW, Baumann A, Muellenbach RM, Roewer N, Wunder C (2010) Carbon monoxide has antioxidative properties in the liver involving p38 MAP kinase pathway in a murine model of systemic inflammation. *Microcirculation* 17:504–513. doi:[10.1111/j.1549-8719.2010.00044.x](https://doi.org/10.1111/j.1549-8719.2010.00044.x)
- Brüne B, Ullrich V (1987) Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase. *Mol Pharmacol* 32:497–504
- Cantley LC (2002) The phosphoinositide 3-kinase pathway. *Science* 296:1655–1657. doi:[10.1126/science.296.5573.1655](https://doi.org/10.1126/science.296.5573.1655)
- Cargnello M, Roux PP (2011) Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. *Microbiol Mol Biol Rev* 75:50–83. doi:[10.1128/MMBR.00031-10](https://doi.org/10.1128/MMBR.00031-10)
- Cepinskas G, Katada K, Bihari A, Potter RF (2008) Carbon monoxide liberated from carbon monoxide-releasing molecule CORM-2 attenuates inflammation in the liver of septic mice. *Am J Physiol* 294:G184–G191. doi:[10.1152/ajpgi.00348.2007](https://doi.org/10.1152/ajpgi.00348.2007)
- Chang T, Wu L, Wang R (2008) Inhibition of vascular smooth muscle cell proliferation by chronic hemin treatment. *Am J Physiol Heart Circ Physiol* 295(3):H999–H1007. doi:[10.1152/ajpheart.01289.2007](https://doi.org/10.1152/ajpheart.01289.2007)
- Cheng S, Lyass A, Massaro JM, O'Connor GT, Keaney JF Jr, Vasan RS (2010) Exhaled carbon monoxide and risk of metabolic syndrome and cardiovascular disease in the community. *Circulation* 122:1470–1477. doi:[10.1161/CIRCULATIONAHA.110.941013](https://doi.org/10.1161/CIRCULATIONAHA.110.941013)
- Chin BY, Jiang G, Wegiel B, Wang HJ, Macdonald T, Zhang XC, Gallo D, Cszimadia E, Bach FH, Lee PJ, Otterbein LE (2007) Hypoxia-inducible factor 1alpha stabilization by carbon monoxide results in cytoprotective preconditioning. *Proc Natl Acad Sci USA* 104:5109–5114. doi:[10.1073/pnas.0609611104](https://doi.org/10.1073/pnas.0609611104)

- Choi BM, Pae HO, Kim YM, Chung HT (2003) Nitric oxide-mediated cytoprotection of hepatocytes from glucose deprivation-induced cytotoxicity: involvement of heme oxygenase-1. *Hepatology* 37:810–823. doi:[10.1053/jhep.2003.50114](https://doi.org/10.1053/jhep.2003.50114)
- Choi YK, Kim CK, Lee H, Jeoung D, Ha KS, Kwon YG, Kim KW, Kim YM (2010) Carbon monoxide promotes VEGF expression by increasing HIF-1 α protein level via two distinct mechanisms, translational activation and stabilization of HIF-1 α protein. *J Biol Chem* 285:32116–32125. doi:[10.1074/jbc.M110.131284](https://doi.org/10.1074/jbc.M110.131284)
- Clark JE, Naughton P, Shurey S, Green CJ, Johnson TR, Mann BE, Foresti R, Motterlini R (2003) Cardioprotective actions by a water-soluble carbon monoxide-releasing molecule. *Circ Res* 93:e2–e8. doi:[10.1161/01.res.0000084381.86567.08](https://doi.org/10.1161/01.res.0000084381.86567.08)
- Coburn RF, Blakemore WS, Forster RE (1963) Endogenous carbon monoxide production in man. *J Clin Invest* 42:1172–1178. doi:[10.1172/jci104802](https://doi.org/10.1172/jci104802)
- Dallas ML, Scragg JL, Peers C (2009) Inhibition of L-type Ca(2+) channels by carbon monoxide. *Adv Exp Med Biol* 648:89–95. doi:[10.1007/978-90-481-2259-2_10](https://doi.org/10.1007/978-90-481-2259-2_10)
- Datta PK, Gross EJ, Lianos EA (2002) Interactions between inducible nitric oxide synthase and heme oxygenase-1 in glomerulonephritis. *Kidney Int* 61:847–850. doi:[10.1046/j.1523-1755.2002.00231.x](https://doi.org/10.1046/j.1523-1755.2002.00231.x)
- Di Pascoli M, Rodella L, Sacerdoti D, Bolognesi M, Turkseven S, Abraham NG (2006) Chronic CO levels have [corrected] a beneficial effect on vascular relaxation in diabetes. *Biochem Biophys Res Commun* 340:935–943. doi:[10.1016/j.bbrc.2005.12.082](https://doi.org/10.1016/j.bbrc.2005.12.082)
- Dijkstra G, Blokzijl H, Bok L, Homan M, van Goor H, Faber KN, Jansen PL, Moshage H (2004) Opposite effect of oxidative stress on inducible nitric oxide synthase and haem oxygenase-1 expression in intestinal inflammation: anti-inflammatory effect of carbon monoxide. *J Pathol* 204:296–303. doi:[10.1002/path.1656](https://doi.org/10.1002/path.1656)
- Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. *Nature* 399:601–605. doi:[10.1038/21224](https://doi.org/10.1038/21224)
- Dioum EM, Rutter J, Tuckerman J, Gonzalez G, Gilles-Gonzalez M, McKnight S (2002) NPAS2: a gas-responsive transcription factor. *Science* 298:2385–2387. doi:[10.1126/science.1078456](https://doi.org/10.1126/science.1078456)
- Dong DL, Zhang Y, Lin DH, Chen J, Patschan S, Goligorsky MS, Nasjletti A, Yang BF, Wang WH (2007) Carbon monoxide stimulates the Ca2(+)-activated big conductance k channels in cultured human endothelial cells. *Hypertension* 50:643–651. doi:[10.1161/HYPERTENSIONAHA.107.096057](https://doi.org/10.1161/HYPERTENSIONAHA.107.096057)
- Douglas CG, Haldane JS, Haldane JB (1912) The laws of combination of haemoglobin with carbon monoxide and oxygen. *J Physiol* 44:275–304
- Dubuis E, Potier M, Wang R, Vandier C (2005) Continuous inhalation of carbon monoxide attenuates hypoxic pulmonary hypertension development presumably through activation of BKCa channels. *Cardiovasc Res* 65:751–761. doi:[10.1016/j.cardiores.2004.11.007](https://doi.org/10.1016/j.cardiores.2004.11.007)
- Dulak J, Józkowicz A, Foresti R, Kasza A, Frick M, Huk I, Green CJ, Pachinger O, Weidinger F, Motterlini R (2002) Heme oxygenase activity modulates vascular endothelial growth factor synthesis in vascular smooth muscle cells. *Antioxid Redox Signal* 4(2):229–240. doi:[10.1089/152308602753666280](https://doi.org/10.1089/152308602753666280)
- Durante W (2011) Protective role of heme oxygenase-1 against inflammation in atherosclerosis. *Front Biosci* 17:2372–2388. doi:[10.2741/3860](https://doi.org/10.2741/3860)
- Estabrook RW, Franklin MR, Hildebrandt AG (1970) Factors influencing the inhibitory effect of carbon monoxide on cytochrome P-450-catalyzed mixed function oxidation reactions. *Ann N Y Acad Sci* 174:218–232
- Fearon IM, Varadi G, Koch S, Isaacsohn I, Ball SG, Peers C (2000) Splice variants reveal the region involved in oxygen sensing by recombinant human L-type Ca(2+) channels. *Circ Res* 87:537–539. doi:[10.1161/01.RES.87.7.537](https://doi.org/10.1161/01.RES.87.7.537)
- Ferrándiz ML, Maicas N, Garcia-Aranda I, Terencio MC, Motterlini R, Devesa I (2008) Treatment with a CO-releasing molecule (CORM-3) reduces joint inflammation and erosion in murine collagen-induced arthritis. *Ann Rheum Dis* 67:1211–1217. doi:[10.1136/ard.2007.082412](https://doi.org/10.1136/ard.2007.082412)
- Finkel T (1998) Oxygen radicals and signaling. *Curr Opin Cell Biol* 10:248–253. doi:[10.1016/S0955-0674\(98\)80147-6](https://doi.org/10.1016/S0955-0674(98)80147-6)

- Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. *Nature* 408:239–247. doi:[10.1038/35041687](https://doi.org/10.1038/35041687)
- Foresti R, Motterlini R (1999) The heme oxygenase pathway and its interaction with nitric oxide in the control of cellular homeostasis. *Free Radic Res* 31:459–475. doi:[10.1080/10715769900301031](https://doi.org/10.1080/10715769900301031)
- Foresti R, Hoque M, Bains S, Green CJ, Motterlini R (2003) Haem and nitric oxide: synergism in the modulation of the endothelial haem oxygenase-1 pathway. *Biochem J* 372:381–390. doi:[10.1042/BJ20021516](https://doi.org/10.1042/BJ20021516)
- Foresti R, Hammad J, Clark JE, Johnson TR, Mann BE, Friebe A, Green CJ, Motterlini R (2004) Vasoactive properties of CORM-3, a novel water-soluble carbon monoxide-releasing molecule. *Br J Pharmacol* 142:453–460. doi:[10.1038/sj.bjp.0705825](https://doi.org/10.1038/sj.bjp.0705825)
- Freitas A, Alves-Filho JC, Secco DD, Neto AF, Ferreira SH, Barja-Fidalgo C, Cunha FQ (2006) Heme oxygenase/carbon monoxide-biliverdin pathway down regulates neutrophil rolling, adhesion and migration in acute inflammation. *Br J Pharmacol* 149:345–354. doi:[10.1038/sj.bjp.0706882](https://doi.org/10.1038/sj.bjp.0706882)
- Frolkis JP, Pothier CE, Blackstone EH, Lauer MS (2003) Frequent ventricular ectopy after exercise as a predictor of death. *N Engl J Med* 348:781–790. doi:[10.1056/NEJMoa022353](https://doi.org/10.1056/NEJMoa022353)
- Fujimoto H, Ohno M, Ayabe S, Kobayashi H, Ishizaka N, Kimura H, Yoshida K, Nagai R (2004) Carbon monoxide protects against cardiac ischemia-reperfusion injury in vivo via MAPK and Akt-eNOS pathways. *Arterioscler Thromb Vasc Biol* 24:1–7. doi:[10.1161/01.ATV.0000142364.85911.0e](https://doi.org/10.1161/01.ATV.0000142364.85911.0e)
- Fujita T, Toda K, Karimova A, Yan SF, Naka Y, Yet SF, Pinsky DJ (2001) Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by derepression of fibrinolysis. *Nat Med* 7:598–604. doi:[10.1038/87929](https://doi.org/10.1038/87929)
- Furchgott RF, Jothianandan D (1991) Endothelium-dependent and -independent vasodilation involving cyclic GMP: relaxation induced by nitric oxide, carbon monoxide and light. *Blood Vessels* 28:52–61
- Furchgott RF, Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature* 288:373–376. doi:[10.1038/288373a0](https://doi.org/10.1038/288373a0)
- Gorman D, Drewry A, Huang YL, Sames C (2003) The clinical toxicology of carbon monoxide. *Toxicology* 187:25–38. doi:[10.1016/S0300-483X\(03\)00005-2](https://doi.org/10.1016/S0300-483X(03)00005-2)
- Guo Y, Stein AB, Wu WJ, Tan W, Zhu X, Li QH, Dawn B, Motterlini R, Bolli R (2004) Administration of a CO-releasing molecule at the time of reperfusion reduced infarct size in vivo. *Am J Physiol Heart Circ Physiol* 286:H1649–H1653. doi:[10.1152/ajpheart.00971.2003](https://doi.org/10.1152/ajpheart.00971.2003)
- Haldane JB (1927) Carbon monoxide as a tissue poison. *Biochem J* 21:1068–1075
- Haschemi A, Chin BY, Jeitler M, Esterbauer H, Wagner O, Bilban M, Otterbein LE (2011) Carbon monoxide induced PPAR γ SUMOylation and UCP2 block inflammatory gene expression in macrophages. *PLoS ONE* 6:e26376. doi:[10.1371/journal.pone.0026376](https://doi.org/10.1371/journal.pone.0026376)
- Hayashi S, Omata Y, Sakamoto H, Higashimoto Y, Hara T, Sagara Y, Noguchi M (2004) Characterization of rat heme oxygenase-3 gene. Implication of processed pseudogenes derived from heme oxygenase-2 gene. *Gene* 336:241–250. doi:[10.1016/j.gene.2004.04.002](https://doi.org/10.1016/j.gene.2004.04.002)
- Henningssson R, Alm P, Ekström P, Lundquist I (1999) Heme oxygenase and carbon monoxide: regulatory roles in islet hormone release: a biochemical, immunohistochemical, and confocal microscopic study. *Diabetes* 48:66–76. doi:[10.2337/diabetes.48.1.66](https://doi.org/10.2337/diabetes.48.1.66)
- Hoetzel A, Dolinay T, Vallbracht S, Zhang Y, Kim HP, Ifedigbo E, Alber S, Kaynar AM, Schmidt R, Ryter SW, Choi AM (2008) Carbon monoxide protects against ventilator-induced lung injury via PPAR-gamma and inhibition of Egr-1. *Am J Respir Crit Care Med* 177:1223–1232. doi:[10.1164/rccm.200708-1265OC](https://doi.org/10.1164/rccm.200708-1265OC)
- Horvath I, Donnelly LE, Kiss A, Paredi P, Kharitonov SA, Barnes PJ (1998a) Elevated levels of exhaled carbon monoxide are associated with an increased expression of heme oxygenase-1 in airway macrophages in asthma: a new marker of chronic inflammation. *Thorax* 53:668–672
- Horvath I, Loukides S, Wodehouse T, Kharitonov SA, Cole PJ, Barnes PJ (1998b) Increased levels of exhaled carbon monoxide in bronchiectasis: a new marker of oxidative stress. *Thorax* 53(867–870):867

- Hou S, Xu R, Heinemann SH, Hoshi T (2008) The RCK1 high-affinity Ca^{2+} sensor confers carbon monoxide sensitivity to Slo1 BK channels. *Proc Natl Acad Sci USA* 105:4039–4043. doi:[10.1073/pnas.0800304105](https://doi.org/10.1073/pnas.0800304105)
- Huang LE, Willmore WG, Gu J, Goldberg MA, Bunn HF (1999) Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. *J Biol Chem* 274:9038–9044. doi:[10.1074/jbc.274.13.9038](https://doi.org/10.1074/jbc.274.13.9038)
- Johnson FK, Durante W, Peyton KJ, Johnson RA (2003) Heme oxygenase inhibitor restores arteriolar nitric oxide function in Dahl rats. *Hypertension* 41:149–155. doi:[10.1161/01.HYP.0000046923.52222.58](https://doi.org/10.1161/01.HYP.0000046923.52222.58)
- Johnson FK, Johnson RA, Durante W, Jackson KE, Stevenson BK, Peyton KJ (2006) Metabolic syndrome increases endogenous carbon monoxide production to promote hypertension and endothelial dysfunction in obese Zucker rats. *J Physiol Regul Integr Comp Physiol* 290:R601–R608. doi:[10.1152/ajpregu.00308.2005](https://doi.org/10.1152/ajpregu.00308.2005)
- Jones RH, Ellicott MF, Cadigan JB, Gaensler EA (1958) The relationship between alveolar and blood carbon monoxide concentrations during breathholding; simple estimation of COHb saturation. *J Lab Clin Med* 51:553–564
- Józkowicz A, Huk I, Nigisch A, Weigel G, Dietrich W, Motterlini R, Dulak J (2004) Heme oxygenase and angiogenic activity of endothelial cells: stimulation by carbon monoxide and inhibition by Tin protoporphyrin-IX. *Antioxid Redox Signal* 5(2):155–162. doi:[10.1089/152308603764816514](https://doi.org/10.1089/152308603764816514)
- Kaide J, Zhang F, Wei Y, Wang W, Gopal VR, Falck JR, Laniado-Schwartzman M, Nasjletti A (2004) Vascular CO counterbalances the sensitizing influence of 20-HETE on agonist-induced vasoconstriction. *Hypertension* 44:210–216. doi:[10.1161/01.HYP.0000135658.57547.bb](https://doi.org/10.1161/01.HYP.0000135658.57547.bb)
- Kharitonov SA, Barnes PJ (2001) Exhaled markers of pulmonary disease. *Am J Respir Crit Care Med* 163:1693–1722
- Kim KM, Pae HO, Zheng M, Park R, Kim YM, Chung HT (2007) Carbon monoxide induces heme oxygenase-1 via activation of protein kinase R-like endoplasmic reticulum kinase and inhibits endothelial cell apoptosis triggered by endoplasmic reticulum stress. *Circ Res* 101:919–927. doi:[10.1161/circresaha.107.154781](https://doi.org/10.1161/circresaha.107.154781)
- Kim HS, Loughran PA, Rao J, Billiar TR, Zuckerbraun BS (2008a) Carbon monoxide activates NF- κ B via ROS generation and Akt pathways to protect against cell death of hepatocytes. *Am J Physiol Gastrointest Liver Physiol* 295:G146–G152. doi:[10.1152/ajpgi.00105.2007](https://doi.org/10.1152/ajpgi.00105.2007)
- Kim HS, Loughran PA, Billiar TR (2008b) Carbon monoxide decreases the level of iNOS protein and active dimer in IL-1 β -stimulated hepatocytes. *Nitric Oxide* 18:256–265. doi:[10.1016/j.niox.2008.02.002](https://doi.org/10.1016/j.niox.2008.02.002)
- Kobayashi A, Ishikawa K, Matsumoto H, Kimura S, Kamiyama Y, Maruyama Y (2007) Synergetic antioxidant and vasodilatory action of carbon monoxide in angiotension II-induced cardiac hypertrophy. *Hypertension* 50:1040–1048. doi:[10.1161/HYPERTENSIONAHA.107.097006](https://doi.org/10.1161/HYPERTENSIONAHA.107.097006)
- Kreck TC, Shade ED, Lamm WJ, McKinney SE, Hlastala MP (2001) Isocapnic hyperventilation increases carbon monoxide elimination and oxygen delivery. *Am J Respir Crit Care Med* 163(2):458–462
- Kruger AL, Peterson SJ, Schwartzman ML, Fusco H, McClung JA, Weiss M, Shenouda S, Goodman AI, Goligorsky MS, Kappas A, Abraham NG (2006) Up-regulation of heme oxygenase provides vascular protection in an animal model of diabetes through its antioxidant and antiapoptotic effects. *J Pharmacol Exp Ther* 319:1144–1152. doi:[10.1124/jpet.106.107482](https://doi.org/10.1124/jpet.106.107482)
- Kubo S, Kurokawa Y, Doe I, Masuko T, Sekiguchi F, Kawabata A (2007) Hydrogen sulfide inhibits activity of three isoforms of recombinant nitric oxide synthase. *Toxicology* 241:92–97. doi:[10.1016/j.tox.2007.08.007](https://doi.org/10.1016/j.tox.2007.08.007)
- Kunisada K, Negoro S, Tone E, Funamoto M, Osugi T, Yamada S, Okabe M, Kishimoto T, Yamauchi-Takahara K (2000) Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. *Proc Natl Acad Sci USA* 97:315–319. doi:[10.1073/pnas.97.1.315](https://doi.org/10.1073/pnas.97.1.315)
- Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ, Winder WW (1999) 5' AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. *Diabetes* 48:1667–1671. doi:[10.2337/diabetes.48.8.1667](https://doi.org/10.2337/diabetes.48.8.1667)

- Lakkisto P, Kytö V, Forsten H, Siren JM, Segersvärd H, Voipio-Pulkki LM, Laine M, Pulkki K, Tikkanen I (2010) Heme oxygenase-1 and carbon monoxide promote neovascularization after myocardial infarction by modulating the expression of HIF-1 α , SDF-1 α and VEGF-B. *Eur J Pharmacol* 635:156–164. doi:[10.1016/j.ejphar.2010.02.050](https://doi.org/10.1016/j.ejphar.2010.02.050)
- Lamon BD, Zhang FF, Puri N, Brodsky SV, Goligorsky MS, Nasjletti A (2009) Dual pathways of carbon monoxide-mediated vasoregulation: modulation by redox mechanisms. *Circ Res* 105:775–783. doi:[10.1161/CIRCRESAHA.109.197434](https://doi.org/10.1161/CIRCRESAHA.109.197434)
- Lavitrano M, Smolenski RT, Musumeci A, Maccherini M, Slominska E, Di Florio E, Bracco A, Mancini A, Stassi G, Patti M, Giovannoni R, Froio A, Simeone F, Forni M, Bacci ML, D'Alise G, Cozzi E, Otterbein LE, Yacoub MH, Bach FH, Calise F (2004) Carbon monoxide improves cardiac energetics and safeguards the heart during reperfusion after cardiopulmonary bypass in pigs. *FASEB J* 1(8):1093–1095
- Lee YC, Martin E, Murad F (2000) Human recombinant soluble guanylyl cyclase: expression, purification, and regulation. *Proc Natl Acad Sci USA* 97:10763–10768. doi:[10.1073/pnas.190336997](https://doi.org/10.1073/pnas.190336997)
- Lee SR, Yang KS, Kwon J, Lee C, Jeong W, Rhee SG (2002) Reversible inactivation of the tumor suppressor PTEN by H₂O₂. *J Biol Chem* 277:20336–20342. doi:[10.1074/jbc.M111899200](https://doi.org/10.1074/jbc.M111899200)
- Leffler CW, Parfenova H, Jaggar JH, Wang R (2006) Carbon monoxide and hydrogen sulfide: gaseous messengers in cerebrovascular circulation. *J Appl Physiol* 100(3):1065–1076. doi:[10.1152/jappphysiol.00793.2005](https://doi.org/10.1152/jappphysiol.00793.2005)
- Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A, Downes CP (2003) Redox regulation of PI 3-kinase signalling via inactivation of PTEN. *EMBO J* 22:5501–5510. doi:[10.1093/emboj/cdg513](https://doi.org/10.1093/emboj/cdg513)
- Li Volti G, Sacerdoti D, Sangras B, Vanella A, Mezentssev A, Scapagnini G, Falck JR, Abraham NG (2005) Carbon monoxide signaling in promoting angiogenesis in human microvessel endothelial cells. *Antioxid Redox Signal* 7(5–6):704–710. doi:[10.1089/ars.2005.7.704](https://doi.org/10.1089/ars.2005.7.704)
- Li A, Xi Q, Umstot ES, Bellner L, Schwartzman ML, Jaggar JH, Leffler CW (2008) Astrocyte-derived CO is a diffusible messenger that mediates glutamate-induced cerebral arteriolar dilation by activating smooth muscle Cell K⁺ channels. *Circ Res* 102:234–241. doi:[10.1161/CIRCRESAHA.107.164145](https://doi.org/10.1161/CIRCRESAHA.107.164145)
- Li L, Hsu A, Moore PK (2009) Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide in the cardiovascular system and in inflammation—a tale of three gases! *Pharmacol Ther* 123(3):386–400. doi:[10.1016/j.pharmthera.2009.05.005](https://doi.org/10.1016/j.pharmthera.2009.05.005)
- Lim I, Gibbons SJ, Lyford GL, Miller SM, Strege PR, Sarr MG, Chatterjee S, Szurszewski JH, Shah VH, Farrugia G (2005) Carbon monoxide activates human intestinal smooth muscle L-type Ca²⁺ channels through a nitric oxide-dependent mechanism. *Am J Physiol Gastrointest Liver Physiol* 288:G7–G14. doi:[10.1152/ajpgi.00205.2004](https://doi.org/10.1152/ajpgi.00205.2004)
- Lin HY, Juan SH, Shen SC, Hsu FL, Chen YC (2003) Inhibition of lipopolysaccharide-induced nitric oxide production by flavonoids in RAW264.7 macrophages involves heme oxygenase-1. *Biochem Pharmacol* 66:1821–1832. doi:[10.1016/S0006-2952\(03\)00422-2](https://doi.org/10.1016/S0006-2952(03)00422-2)
- Lin HH, Lai SC, Chau LY (2011) Heme oxygenase-1/carbon monoxide induces vascular endothelial growth factor expression via p38 kinase-dependent activation of Sp1. *J Biol Chem* 286(5):3829–3838. doi:[10.1074/jbc.M110.168831](https://doi.org/10.1074/jbc.M110.168831)
- Liu DN, Fang Y, Wu LR, Liu XD, Li P, He ZY (2010) Effect of the haeme oxygenase-1/endogenous carbon monoxide system on atherosclerotic plaque formation in rabbits. *Cardiovasc J Afr* 21(5):257–262. doi:[CVJ-21.001](https://doi.org/10.1016/j.cva.2010.02.001)
- Lo Iacono L, Boczkowski J, Zini R, Salouage I, Berdeaux A, Motterlini R, Morin D (2011) A carbon monoxide-releasing molecule (CORM-3) uncouples mitochondrial respiration and modulates the production of reactive oxygen species. *Free Radic Biol Med* 50:1556–1564. doi:[10.1016/j.freeradbiomed.2011.02.033](https://doi.org/10.1016/j.freeradbiomed.2011.02.033)
- Lutter R, van Schaik ML, van Zwieten R, Wever R, Roos D, Hamers MN (1985) Purification and partial characterization of the b-type cytochrome from human polymorphonuclear leukocytes. *J Biol Chem* 260:2237–2244
- Maines MD (1997) The heme oxygenase system: a regulator of second messenger gases. *Annu Rev Pharmacol Toxicol* 37:517–554. doi:[10.1146/annurev.pharmtox.37.1.517](https://doi.org/10.1146/annurev.pharmtox.37.1.517)

- Marks GS, Brien JF, Nakatsu K, McLaughlin BE (1991) Does carbon monoxide have a physiological function? *Trends Pharmacol Sci* 12:185–188. doi:[10.1016/0165-6147\(91\)90544-3](https://doi.org/10.1016/0165-6147(91)90544-3)
- Mayr FB, Spiel A, Leitner J, Marsik C, Germann P, Ullrich R, Wanger O, Jilma B (2005) Effects of carbon monoxide inhalation during experimental endotoxemia in humans. *Am J Respir Crit Care Med* 171:354–360. doi:[10.1164/rccm.200404-446OC](https://doi.org/10.1164/rccm.200404-446OC)
- McCoubrey WK Jr, Huang TJ, Maines MD (1997) Isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3. *Eur J Biochem* 247:725–732. doi:[10.1111/j.1432-1033.1997.00725.x](https://doi.org/10.1111/j.1432-1033.1997.00725.x)
- McDonagh AF (1990) Is bilirubin good for you? *Clin Perinatol* 17:359–369
- Miller TW, Isenberg JS, Roberts DD (2009) Molecular regulation of tumor angiogenesis and perfusion via redox signaling. *Chem Rev* 109(7):3099–3124. doi:[10.1021/cr8005125](https://doi.org/10.1021/cr8005125)
- Mishra S, Fujita T, Lama VN, Nam D, Liao H, Okada M, Minamoto K, Yoshikawa Y, Harada H, Pinsky DJ (2006) Carbon monoxide rescues ischemic lungs by interrupting MAPK-driven expression of early growth response 1 gene and its downstream target genes. *Proc Natl Acad Sci USA* 103:5191–5196. doi:[10.1073/pnas.0600241103](https://doi.org/10.1073/pnas.0600241103)
- Monma M, Yamaya M, Sekizawa K, Ikeda K, Suzuki N, Kikuchi T, Takasaka T, Sasaki H (1999) Increased carbon monoxide in exhaled air of patients with seasonal allergic rhinitis. *Clin Exp Allergy* 29:1537–1541. doi:[10.1046/j.1365-2222.1999.00684.x](https://doi.org/10.1046/j.1365-2222.1999.00684.x)
- Morita T, Kourembanas S (1995) Endothelial cell expression of vasoconstrictors and growth factors is regulated by smooth muscle cell-derived carbon monoxide. *J Clin Invest* 96:2676–2682. doi:[10.1172/jci118334](https://doi.org/10.1172/jci118334)
- Morita T, Mitsialis SA, Koike H, Liu Y, Kourembanas S (1997) Carbon monoxide controls the proliferation of hypoxic vascular smooth muscle cells. *J Biol Chem* 272:32804–32809. doi:[10.1074/jbc.272.52.32804](https://doi.org/10.1074/jbc.272.52.32804)
- Mortia T, Kourembanas S (1995) Endothelial cell expression of vasoconstrictors and growth factors is regulated by smooth muscle cell-derived carbon monoxide. *J Clin Invest* 96:2676–2682. doi:[10.1172/jci118334](https://doi.org/10.1172/jci118334)
- Mosén H, Salehi A, Alm P, Henningsson R, Jimenez-Feltström J, Ostenson CG, Efendic S, Lundquist I (2004) Defective glucose-stimulated insulin release in the diabetic Goto-Kakizaki (GK) rat coincides with reduced activity of the islet carbon monoxide signaling pathway. *Endocrinology* 146:1553–1558. doi:[10.1210/en.2004-0851](https://doi.org/10.1210/en.2004-0851)
- Mosén H, Salehi A, Henningsson R, Lundquist I (2006) Nitric oxide inhibits, and carbon monoxide activates, islet acid alpha-glucosidase activities in parallel with glucose-stimulated insulin secretion. *J Endocrinol* 190:681–693. doi:[10.1677/joe.1.06890](https://doi.org/10.1677/joe.1.06890)
- Motterlini R, Otterbein LE (2010) The therapeutic potential of carbon monoxide. *Nat Rev Drug Discov* 9(9):728–743. doi:[10.1038/nrd3228](https://doi.org/10.1038/nrd3228)
- Motterlini R, Foresti R, Intaglietta M, Winslow RM (1997) NO-mediated activation of heme oxygenase: endogenous cytoprotection against oxidative stress to endothelium. *Am J Physiol* 270:H107–H114
- Motterlini R, Clark JE, Foresti R, Sarathchandra P, Mann BE, Green CJ (2002a) Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. *Circ Res* 90:E17–E24. doi:[10.1161/hh0202.104530](https://doi.org/10.1161/hh0202.104530)
- Motterlini R, Green CJ, Foresti R (2002b) Regulation of heme oxygenase-1 by redox signals involving nitric oxid. *Antioxid Redox Signal* 4:615–624. doi:[10.1089/15230860260220111](https://doi.org/10.1089/15230860260220111)
- Mustafa AK, Gadalla MM, Snyder SH (2009) Signaling by gasotransmitters. *Sci Signal* 2:re2. doi:[10.1126/scisignal.268re2](https://doi.org/10.1126/scisignal.268re2)
- Nakahira K, Kim HP, Geng XH, Nakao A, Wang X, Murase N, Drain PF, Wang X, Sasidhar M, Nabel EG, Takahashi T, Lukacs NW, Ryter SW, Morita K, Choi AM (2006) Carbon monoxide differentially inhibits TLR signaling pathways by regulating ROS-induced trafficking of TLRs to lipid rafts. *J Exp Med* 203:2377–2389. doi:[10.1084/jem.20060845](https://doi.org/10.1084/jem.20060845)
- Nakao A, Faleo G, Nalesnik MA, Seda-Neto J, Kohmoto J, Murase N (2009) Low-dose carbon monoxide inhibits progressive chronic allograft nephropathy and restores renal allograft function. *Am J Physiol Renal Physiol* 297:F19–F26. doi:[10.1152/ajprenal.90728.2008](https://doi.org/10.1152/ajprenal.90728.2008)

- Nakao A, Huang CS, Stolz DB, Wang Y, Franks JM, Tochigi N, Billiar TR, Toyoda Y, Tzeng E, McCurry KR (2011) Ex vivo carbon monoxide delivery inhibits intimal hyperplasia in arterialized vein grafts. *Cardiovasc Res* 89:457–463. doi:[10.1093/cvr/cvq298](https://doi.org/10.1093/cvr/cvq298)
- Naughton P, Hoque M, Green CJ, Foresti R, Motterlini R (2002) Interaction of heme with nitroxyl or nitric oxide amplifies heme oxygenase-1 induction: involvement of the transcription factor Nrf2. *Cell Mol Biol (Noisy-le-grand)* 48:885–894
- Ndisang JF, Zhao W, Wang R (2002) Selective regulation of blood pressure by heme oxygenase-1 in hypertension. *Hypertension* 40(3):315–321. doi:[10.1161/01.HYP.0000028488.71068.16](https://doi.org/10.1161/01.HYP.0000028488.71068.16)
- Ndisang JF, Wu L, Zhao W, Wang R (2003) Induction of heme oxygenase-1 and stimulation of cGMP production by hemin in aortic tissues from hypertensive rats. *Blood* 101(10):3893–3900. doi:[10.1182/blood-2002-08-2608](https://doi.org/10.1182/blood-2002-08-2608)
- Ndisang JF, Tabien HE, Wang R (2004) Carbon monoxide and hypertension. *J Hypertens* 22:1057–1074
- Negoro S, Kunisada K, Fujio Y, Funamoto M, Darville MI, Eizirik DL, Osugi T, Izumi M, Oshima Y, Nakaoka Y, Hirota H, Kishimoto T, Yamauchi-Takahara K (2001) Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. *Circulation* 104:979–981. doi:[10.1161/hc3401.095947](https://doi.org/10.1161/hc3401.095947)
- Nicolai A, Li M, Kim DH, Peterson SJ, Vanella L, Positano V, Gastaldelli A, Rezzani R, Rodella LF, Drummond G, Kusmic G, L'Abbate A, Kappas A, Abraham NG (2009) Heme oxygenase-1 induction remodels adipose tissue and improves insulin sensitivity in obesity-induced diabetic rats. *Hypertension* 53:508–515. doi:[10.1161/HYPERTENSIONAHA.108.124701](https://doi.org/10.1161/HYPERTENSIONAHA.108.124701)
- Nikberg II, Murashko VA, Leonenko IN (1972) Carbon monoxide concentration in the air exhaled by the healthy and the ill. *Vrach Delo* 12:112–114
- Nisimoto Y, Otsuka-Murakami H, Iwata S (1994) NADPH-cytochrome c reductase from human neutrophil membranes: purification, characterization and localization. *Biochem J* 297(Pt 3):585–593
- Nizamutdinova IT, Kim YM, Kim HJ, Seo HG, Lee JH, Chang KC (2009) Carbon monoxide (from CORM-2) inhibits high glucose-induced ICAM-1 expression via AMP-activated protein kinase and PPAR-gamma activations in endothelial cells. *Atherosclerosis* 207:405–411. doi:[10.1016/j.atherosclerosis.2009.05.008](https://doi.org/10.1016/j.atherosclerosis.2009.05.008)
- Oh GS, Pae HO, Lee BS, Kim BN, Kim JM, Kim HR, Jeon SB, Jeon WK, Chae HJ, Chung HT (2006) Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide. *Free Radic Biol Med* 41:106–119. doi:[10.1016/j.freeradbiomed.2006.03.021](https://doi.org/10.1016/j.freeradbiomed.2006.03.021)
- Okinaga S, Shibahara S (1993) Identification of a nuclear protein that constitutively recognizes the sequence containing a heat-shock element. Its binding properties and possible function modulating heat-shock induction of the rat heme oxygenase gene. *Eur J Biochem* 212(1):167–175. doi:[10.1111/j.1432-1033.1993.tb17647.x](https://doi.org/10.1111/j.1432-1033.1993.tb17647.x)
- Otterbein LE, Mantell LL, Choi AM (1999) Carbon monoxide provides protection against hyperoxic lung injury. *Am J Physiol* 276:L688–L694
- Otterbein LE, Bach FH, Alam J, Soares M, Tao LuH, Wysk M, Davis RJ, Flavell RA, Choi AM (2000) Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. *Nat Med* 6:422–428. doi:[10.1038/74680](https://doi.org/10.1038/74680)
- Otterbein LE, Otterbein SL, Ifedigbo E, Liu F, Morse DE, Fearn C, Ulevitch RJ, Knickelbein R, Flavell RA, Choi AM (2003a) MKK3 mitogen-activated protein kinase pathway mediates carbon monoxide-induced protection against oxidant-induced lung injury. *Am J Pathol* 163:2555–2563. doi:[10.1016/S0002-9440\(10\)63610-3](https://doi.org/10.1016/S0002-9440(10)63610-3)
- Otterbein LE, Zuckerbraun BS, Haga M, Liu F, Song R, Usheva A, Stachulak C, Bodyak N, Smith RN, Csizmadia E, Tyagi S, Akamatsu Y, Flavell RJ, Billiar TR, Tzeng E, Bach FH, Choi AM, Soares MP (2003b) Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. *Nat Med* 9:183–190. doi:[10.1038/nm817](https://doi.org/10.1038/nm817)
- Otterbein LE, May A, Chin BY (2005) Carbon monoxide increases macrophage bacterial clearance through Toll-like receptor (TLR)4 expression. *Cell Mol Biol (Noisy-le-grand)* 51(5):433–440

- Pae HO, Oh GS, Choi BM, Chae SC, Kim YM, Chung KR, Chung HT (2004) Carbon monoxide produced by heme oxygenase-1 suppresses T cell proliferation via inhibition of IL-2 production. *J Immunol* 172:4744–4751
- Paredi P, Biernacki W, Invernizzi G, Kharitonov SA, Barnes PJ (1999) Exhaled carbon monoxide levels elevated in diabetes and correlated with glucose concentration in blood: a new test for monitoring the disease? *Chest* 116:1007–1111. doi:[10.1378/chest.116.4.1007](https://doi.org/10.1378/chest.116.4.1007)
- Paredi P, Kharitonov SA, Leak D, Shah PL, Cramer D, Hodson ME, Barnes PJ (2000) Exhaled ethane is elevated in cystic fibrosis and correlates with carbon monoxide levels and airway obstruction. *Am J Respir Crit Care Med* 161:1247–1251
- Peyton KJ, Reyna SV, Chapman GB, Ensenat D, Liu XM, Wang H, Schafer AI, Durante W (2002) Heme oxygenase-1-derived carbon monoxide is an autocrine inhibitor of vascular smooth muscle cell growth. *Blood* 99:4443–4448. doi:[10.1182/blood.V99.12.4443](https://doi.org/10.1182/blood.V99.12.4443)
- Piantadosi CA (2008) Carbon monoxide, reactive oxygen signaling, and oxidative stress. *Free Radic Biol Med* 45:562–569. doi:[10.1016/j.freeradbiomed.2008.05.013](https://doi.org/10.1016/j.freeradbiomed.2008.05.013)
- Polizio AH, Santa-Cruz DM, Balestrasse KB, Gironacci MM, Bertera FM, Höcht C, Taira CA, Tomaro ML, Gorzalczy S (2011) Heme oxygenase-1 overexpression fails to attenuate hypertension when the nitric oxide synthase system is not fully operative. *Pharmacology* 87:341–349. doi:[10.1159/000327939](https://doi.org/10.1159/000327939)
- Polte T, Abata A, Dennerly PA, Schröder H (2000) Heme oxygenase-1 is a cGMP-inducible endothelial protein and mediates the cytoprotective action of nitric oxide. *Arterioscler Thromb Vasc Biol* 20:1209–1215. doi:[10.1161/01.atv.20.5.1209](https://doi.org/10.1161/01.atv.20.5.1209)
- Qingyou Z, Junbao D, Weijin Z, Hui Y, Chaoshu T, Chunyu Z (2004) Impact of hydrogen sulfide on carbon monoxide/heme oxygenase pathway in the pathogenesis of hypoxic pulmonary hypertension. *Biochem Biophys Res Commun* 317:30–37. doi:[10.1016/j.bbrc.2004.02.176](https://doi.org/10.1016/j.bbrc.2004.02.176)
- Queiroga CS, Almeida AS, Alves PM, Brenner C, Vieira HL (2011) Carbon monoxide prevents hepatic mitochondrial membrane permeabilization. *BMC Cell Biol* 12:10. doi:[10.1186/1471-2121-12-10](https://doi.org/10.1186/1471-2121-12-10)
- Raman KG, Barbato JE, Ifedigbo E, Ozanich BA, Zenati MS, Otterbein LE, Tzeng E (2006) Inhaled carbon monoxide inhibits intimal hyperplasia and provides added benefit with nitric oxide. *J Vasc Surg* 44:151–158. doi:[10.1016/j.jvs.2006.04.004](https://doi.org/10.1016/j.jvs.2006.04.004)
- Ramlawi B, Scott JR, Feng J, Mieno S, Raman KG, Gallo D, Csizmadia E, Yoke Chin B, Bach FH, Otterbein LE, Selke FW (2007) Inhaled carbon monoxide prevents graft-induced intimal hyperplasia in swine. *J Surg Res* 138:121–127. doi:[10.1016/j.jss.2006.08.031](https://doi.org/10.1016/j.jss.2006.08.031)
- Ramos KS, Lin H, McGrath JJ (1989) Modulation of cyclic guanosine monophosphate levels in cultured aortic smooth muscle cells by carbon monoxide. *Biochem Pharmacol* 38:1368–1370
- Rémy S, Blancou P, Tesson L, Tardif V, Brion R, Royer PJ, Motterlini R, Foresti R, Painchaud M, Pogu S, Gregoire M, Bach JM, Anegón I, Chauveau C (2009) Carbon monoxide inhibits TLR-induced dendritic cell immunogenicity. *J Immunol* 182:1877–1884. doi:[10.4049/jimmunol.0802436](https://doi.org/10.4049/jimmunol.0802436)
- Ricote M, Li A, Willson T, Kelly C, Glass C (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. *Nature* 391:79–82. doi:[10.1038/34178](https://doi.org/10.1038/34178)
- Riesco-Fagundo AM, Pérez-García MT, González C, López-López JR (2001) O(2) modulates large-conductance Ca(2+)-dependent K(+) channels of rat chemoreceptor cells by a membrane-restricted and CO-sensitive mechanism. *Circ Res* 89:430–436. doi:[10.1161/hh1701.095632](https://doi.org/10.1161/hh1701.095632)
- Roberts P, Youn H, Kerby R (2004) CO-sensing mechanisms. *Microbiol Mol Biol Rev* 68:453–473. doi:[10.1128/MMBR.68.3.453-473.2004](https://doi.org/10.1128/MMBR.68.3.453-473.2004)
- Ryter SW, Choi AM (2007) Cytoprotective and anti-inflammatory actions of carbon monoxide in organ injury and sepsis models. *Novartis Found Symp* 280:165–181. doi:[10.1124/jpet.108.148049](https://doi.org/10.1124/jpet.108.148049)
- Ryter SW, Otterbein LE (2004) Carbon monoxide in biology and medicine. *BioEssays* 26:270–280. doi:[10.1002/bies.20005](https://doi.org/10.1002/bies.20005)
- Sato K, Balla J, Otterbein L, Smith RN, Brouard S, Lin Y, Csizmadia E, Sevigny J, Robson SC, Vercellotti G, Choi AM, Bach FH, Soares MP (2001) Carbon monoxide generated by heme oxygenase-1 suppresses the rejection of mouse-to-rat cardiac transplants. *J Immunol* 166:4185–4194

- Sawle P, Foresti R, Mann BE, Johnson TR, Green CJ, Motterlini R (2005) Carbon monoxide-releasing molecules (CO-RMs) attenuate the inflammatory response elicited by lipopolysaccharide in RAW264.7 murine macrophages. *Br J Pharmacol* 145:800–810. doi:[10.1038/sj.bjp.0706241](https://doi.org/10.1038/sj.bjp.0706241)
- Scruggs JL, Dallas ML, Wilkinson JA, Varadi G, Peers C (2008) Carbon monoxide inhibits L-type Ca^{2+} channels via redox modulation of key cysteine residues by mitochondrial reactive oxygen species. *J Biol Chem* 283:24412–24419. doi:[10.1074/jbc.M803037200](https://doi.org/10.1074/jbc.M803037200)
- Semenza GL (2007) Hypoxia-inducible factor 1 (HIF-1) pathway. *Sci STKE* 2007:cm8. doi:[10.1126/stke.4072007cm8](https://doi.org/10.1126/stke.4072007cm8)
- Shamloul R, Wang R (2005) Monitoring circulatory heme level in hemin therapy for lowering blood pressure in rats. *Cell Mol Biol (Noisy-le-grand)* 51(5):507–512
- Shibahara S, Müller RM (1987) Taguchi H (Transcriptional control of rat heme oxygenase by heat shock). *J Biol Chem* 262(27):12889–12892
- Sjöstrand T (1949) Endogenous formation of carbon monoxide in man under normal and pathological conditions. *Scand J Clin Lab Invest* 1:201–214
- Sjöstrand T (1951) Endogenous formation of carbon monoxide; the CO concentration in the inspired and expired air of hospital patients. *Acta Physiol Scand* 22:137–141
- Song R, Mahidhara RS, Liu F, Ning W, Otterbein LE, Choi AM (2002) Carbon monoxide inhibits human airway smooth muscle cell proliferation via mitogen-activated protein kinase pathway. *Am J Respir Cell Mol Biol* 27:603–610. doi:[10.1165/rcmb.4851](https://doi.org/10.1165/rcmb.4851)
- Stein AB, Guo Y, Tan W, Wu WJ, Zhu X, Li Q, Luo C, Dawn B, Johnson TR, Motterlini R, Bolli R (2005) Administration of a CO-releasing molecule induces late preconditioning against myocardial infarction. *J Mol Cell Cardiol* 38:127–134. doi:[10.1016/j.yjmcc.2004.10.006](https://doi.org/10.1016/j.yjmcc.2004.10.006)
- Stephanou A, Latchman DS (1999) Transcriptional regulation of the heat shock protein genes by STAT family transcription factors. *Gene Exp* 7:311–319
- Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN (1987) Bilirubin is an antioxidant of possible physiological importance. *Science* 235:1043–1046. doi:[10.1126/science.3029864](https://doi.org/10.1126/science.3029864)
- Stone JR, Marletta MA (1994) Soluble guanylate cyclase from bovine lung: activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. *Biochemistry* 33:5636–5640. doi:[10.1021/bi00184a036](https://doi.org/10.1021/bi00184a036)
- Stoppani J, Hildebrandt AL, Sakamoto K, Cameron-Smith D, Goodyear LJ, Neuffer PD (2002) AMP-activated protein kinase activates transcription of the UCP3 and HKII genes in rat skeletal muscle. *Am J Physiol* 283:E1239–E1248. doi:[10.1152/ajpendo.00278.2002](https://doi.org/10.1152/ajpendo.00278.2002)
- Suematsu M, Goda N, Santo T, Kashiwagi S, Egawa T, Shinoda Y, Ishimura Y (1995) Carbon monoxide: an endogenous modulator of sinusoidal tone in the perfused rat liver. *J Clin Invest* 96:2431–2437. doi:[10.1172/JCI118300](https://doi.org/10.1172/JCI118300)
- Suh GY, Jin Y, Yi AK, Wang XM, Choi AM (2006) CCAAT/enhancer-binding protein mediates carbon monoxide-induced suppression of cyclooxygenase-2. *Am J Respir Cell Mol Biol* 35:220–226. doi:[10.1165/rcmb.2005-0154OC](https://doi.org/10.1165/rcmb.2005-0154OC)
- Suliman HB, Carraway MS, Tatro LG, Piantadosi CA (2007) A new activating role for CO in cardiac mitochondrial biogenesis. *J Cell Sci* 120:299–308. doi:[10.1242/jcs.03318](https://doi.org/10.1242/jcs.03318)
- Taillé C, El-Benna J, Lanone S, Boczkowski J, Motterlini R (2005) Mitochondrial respiratory chain and NAD(P)H oxidase are targets for the antiproliferative effect of carbon monoxide in human airway smooth muscle. *J Biol Chem* 280:25350–25360. doi:[10.1074/jbc.M503512200](https://doi.org/10.1074/jbc.M503512200)
- Teleshkin V, Brazier SP, Mears R, Müller CT, Riccardi D, Kemp PJ (2011) Cysteine residue 911 in C-terminal tail of human BK(Ca) α channel subunit is crucial for its activation by carbon monoxide. *Pflugers Arch* 461:665–675. doi:[10.1007/s00424-011-0924-7](https://doi.org/10.1007/s00424-011-0924-7)
- Tenhunen R, Marver HS, Schmid R (1968) The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. *Proc Natl Acad Sci USA* 61:748–755
- Tenhunen R, Marver HS, Schmid R (1969) Microsomal heme oxygenase. Characterization of the enzyme. *J Biol Chem* 244:6388–6394
- Tsoyi K, Ha YM, Kim YM, Lee YS, Kim HJ, Kim HJ, Seo HG, Lee JH, Chang KC (2009) Activation of PPAR- γ by carbon monoxide from CORM-2 leads to the inhibition of iNOS but not COX-2 expression in LPS-stimulated macrophages. *Inflammation* 32:364–371. doi:[10.1007/s10753-009-9144-0](https://doi.org/10.1007/s10753-009-9144-0)

- Turcanu V, Dhouib M, Poindron P (1998) Nitric oxide synthase inhibition by haem oxygenase decreases macrophage nitric-oxide-dependent cytotoxicity: a negative feedback mechanism for the regulation of nitric oxide production. *Res Immunol* 149:741–744
- Uemura K, Adachi-Akahane S, Shintani-Ishida K, Yoshida K (2005) Carbon monoxide protects cardiomyogenic cells against ischemic death through L-type Ca^{2+} channel inhibition. *Biochem Biophys Res Commun* 334:661–668. doi:[10.1016/j.bbrc.2005.06.142](https://doi.org/10.1016/j.bbrc.2005.06.142)
- Urquhart P, Rosignoli G, Cooper D, Motterlini R, Perretti M (2007) Carbon monoxide-releasing molecules modulate leukocyte-endothelial interactions under flow. *J Pharmacol Exp Ther* 321:656–662. doi:[10.1124/jpet.106.117218](https://doi.org/10.1124/jpet.106.117218)
- Van Landeghem L, Laleman W, Vander Elst I, Zeegers M, Van Pelt J, Cassiman D, Nevens F (2009) Carbon monoxide produced by intrasinusoidally located haem-oxygenase-1 regulates the vascular tone in cirrhotic rat liver. *Liver Int* 29:650–660. doi:[10.1111/j.1478-3231.2008.01857.x](https://doi.org/10.1111/j.1478-3231.2008.01857.x)
- Verma A, Hirsch DJ, Glatt CE, Ronnett GV, Snyder SH (1993) Carbon monoxide: a putative neural messenger. *Science* 259:381–384. doi:[10.1126/science.7678352](https://doi.org/10.1126/science.7678352)
- Vicente AM, Guillen MI, Alcaraz MJ (2001) Modulation of haem oxygenase-1 expression by nitric oxide and leukotrienes in zymosan-activated macrophages. *Br J Pharmacol* 133:920–926. doi:[10.1038/sj.bjp.0704145](https://doi.org/10.1038/sj.bjp.0704145)
- Von Berg R (1999) Toxicology update: carbon monoxide. *J Appl Toxicol* 19:379–386. doi:[10.1002/\(SICI\)1099-1263\(199909/10\)19:5<379:AID-JAT563>3.0.CO;2-8](https://doi.org/10.1002/(SICI)1099-1263(199909/10)19:5<379:AID-JAT563>3.0.CO;2-8)
- Vreman HJ, Wong RJ, Stevenson DK (2001) Carbon monoxide and cardiovascular functions. Chapter 15. Sources, Sinks, and Measurement of Carbon Monoxide. CRC Press, Boca Raton
- Wagner CT, Durante W, Christodoulides N, Hellums JD, Schafer AI (1997) Hemodynamic forces induce the expression of heme oxygenase in cultured vascular smooth muscle cells. *J Clin Invest* 100:589–596. doi:[10.1172/JCI119569](https://doi.org/10.1172/JCI119569)
- Wang R (1998) Resurgence of carbon monoxide: an endogenous gaseous vasorelaxing factor. *Can J Physiol Pharmacol* 76:1–15
- Wang R (2002) Two's company, three's a crowd: can H_2S be the third endogenous gaseous transmitter? *FASEB J* 16(13):1792–1798. doi:[10.1096/fj.02-0211hyp](https://doi.org/10.1096/fj.02-0211hyp)
- Wang R, Wu L (1997) The chemical modification of K Ca channels by carbon monoxide in vascular smooth muscle cells. *J Biol Chem* 272:8222–8226. doi:[10.1074/jbc.272.13.8222](https://doi.org/10.1074/jbc.272.13.8222)
- Wang R, Wu L, Wang Z (1997a) The direct effect of carbon monoxide on K Ca channels in vascular smooth muscle cells. *Pflugers Arch* 434:285–291
- Wang R, Wang Z, Wu L (1997b) Carbon monoxide-induced vasorelaxation and the underlying mechanisms. *Br J Pharmacol* 121(5):927–934. doi:[10.1038/sj.bjp.0701222](https://doi.org/10.1038/sj.bjp.0701222)
- Wang R, Wang Z, Wu L, Hanna ST, Peterson-Wakeman R (2001) Reduced vasorelaxant effect of carbon monoxide in diabetes and the underlying mechanisms. *Diabetes* 50(1):166–174. doi:[10.2337/diabetes.50.1.166](https://doi.org/10.2337/diabetes.50.1.166)
- Wang R, Shamloul R, Wang X, Meng Q, Wu L (2006) Sustained normalization of high blood pressure in spontaneously hypertensive rats by implanted hemin pump. *Hypertension* 48(4):685–692. doi:[10.1161/01.HYP.0000239673.80332.2f](https://doi.org/10.1161/01.HYP.0000239673.80332.2f)
- Wang X, Wang Y, Kim HP, Nakahira K, Ryter SW, Choi AM (2007) Carbon monoxide protects against hyperoxia-induced endothelial cell apoptosis by inhibiting reactive oxygen species formation. *J Biol Chem* 282:1718–1726. doi:[10.1074/jbc.M607610200](https://doi.org/10.1074/jbc.M607610200)
- Wang S, Publicover S, Gu Y (2009) An oxygen-sensitive mechanism in regulation of epithelial sodium channel. *Proc Natl Acad Sci USA* 106:2957–2962. doi:[10.1073/pnas.0809100106](https://doi.org/10.1073/pnas.0809100106)
- Weaver LK (1999) Carbon monoxide poisoning. *Crit Care Clin* 15:297–317
- Wegiel B, Gallo DJ, Raman KG, Karlsson JM, Ozanich B, Chin BY, Tzeng E, Ahmad S, Ahmed A, Baty CJ, Otterbein LE (2010) Nitric oxide-dependent bone marrow progenitor mobilization by carbon monoxide enhances endothelial repair after vascular injury. *Circulation* 121:537–548. doi:[10.1161/CIRCULATIONAHA.109.887695](https://doi.org/10.1161/CIRCULATIONAHA.109.887695)
- Wei Y, Chen P, de Bruyn M, Zhang W, Bremer E, Helfrich W (2010) Carbon monoxide-releasing molecule-2 (CORM-2) attenuates acute hepatic ischemia reperfusion injury in rats. *BMC Gastroenterol* 10:42. doi:[10.1186/1471-230X-10-42](https://doi.org/10.1186/1471-230X-10-42)

- Wilkinson WJ, Kemp PJ (2011a) Carbon monoxide: an emerging regulator of ion channels. *J Physiol* 589:3055–3062. doi:[10.1113/jphysiol.2011.206706](https://doi.org/10.1113/jphysiol.2011.206706)
- Wilkinson WJ, Kemp PJ (2011b) The carbon monoxide donor, CORM-2, is an antagonist of ATP-gated, human P2X4 receptors. *Purinergic Signal* 7:57–64. doi:[10.1007/s11302-010-9213-8](https://doi.org/10.1007/s11302-010-9213-8)
- Wilkinson WJ, Gadeberg HC, Harrison AW, Allen ND, Riccardi D, Kemp PJ (2009) Carbon monoxide is a rapid modulator of recombinant and native P2X(2) ligand-gated ion channels. *Br J Pharmacol* 158:862–871. doi:[10.1111/j.1476-5381.2009.00354.x](https://doi.org/10.1111/j.1476-5381.2009.00354.x)
- Williams SE, Wootton P, Mason HS, Bould J, Iles DE, Riccardi D, Peers C, Kemp PJ (2004) Hemoxxygenase-2 is an oxygen sensor for a calcium-sensitive potassium channel. *Science* 306:2093–2097. doi:[10.1126/science.1105010](https://doi.org/10.1126/science.1105010)
- Woo CH, Massett MP, Shishido T, Itoh S, Ding B, McClain C, Che W, Vulapalli SR, Yan C, Abe J (2006) ERK5 activation inhibits inflammatory responses via peroxisome proliferator-activated receptor delta (PPARdelta) stimulation. *J Biol Chem* 281:32164–32174. doi:[10.1074/jbc.M602369200](https://doi.org/10.1074/jbc.M602369200)
- Wu L, Wang R (2005) Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. *Pharmacol Rev* 57(4):585–630. doi:[10.1124/pr.57.4.3](https://doi.org/10.1124/pr.57.4.3)
- Wu L, Cao K, Lu Y, Wang R (2002) Different mechanisms underlying the stimulation of KCa channels by nitric oxide and carbon monoxide. *J Clin Invest* 110(5):691–700. doi:[10.1172/JCI0215316](https://doi.org/10.1172/JCI0215316)
- Yamaya M, Sekizawa K, Ishizuka S, Monma M, Mizuta K, Sasaki H (1998) Increased carbon monoxide in exhaled air of subjects with upper respiratory tract infections. *Am J Respir Crit Care Med* 158(1):311–314
- Yamaya M, Hosoda M, Ishizuka S, Monma M, Matsui T, Suzuki T, Sekizawa K, Sasaki H (2001) Relation between exhaled carbon monoxide levels and clinical severity of asthma. *Clin Exp Allergy* 31:417–422. doi:[10.1046/j.1365-2222.2001.01013.x](https://doi.org/10.1046/j.1365-2222.2001.01013.x)
- Zakhary R, Gaine SP, Dinerman JL, Ruat M, Flavahan NA, Snyder SH (1996) Heme oxygenase 2: endothelial and neuronal localization and role in endothelium-dependent relaxation. *Proc Natl Acad Sci USA* 93:795–798. doi:[10.1073/pnas.93.2.795](https://doi.org/10.1073/pnas.93.2.795)
- Zakhary R, Poss KD, Jaffrey SR, Ferris CD, Tonegawa S, Snyder SH (1997) Targeted gene deletion of heme oxygenase 2 reveals neural role for carbon monoxide. *Proc Natl Acad Sci USA* 94:14848–14853. doi:[10.1073/pnas.94.26.14848](https://doi.org/10.1073/pnas.94.26.14848)
- Zayasu K, Sekizawa K, Okinaga S, Yamaya M, Ohru T, Sasaki H (1997) Increased carbon monoxide in exhaled air of asthmatic patients. *Am J Respir Crit Care Med* 156:1140–1143
- Zhang X, Shan P, Alam J, Fu XY, Lee PL (2005) Carbon monoxide differentially modulates STAT1 and STAT3 and inhibits apoptosis via a phosphatidylinositol 3-kinase/Akt and p38 kinase-dependent STAT3 pathway during anoxia-reoxygenation injury. *J Biol Chem* 280:8714–8721. doi:[10.1074/jbc.M408092200](https://doi.org/10.1074/jbc.M408092200)
- Zhang X, Shan P, Jiang G, Zhang SS, Otterbein LE, Fu XY, Lee PJ (2006) Endothelial STAT3 is essential for the protective effects of HO-1 in oxidant-induced lung injury. *FASEB J* 20:2156–2158. doi:[10.1096/fj.06-5668fje](https://doi.org/10.1096/fj.06-5668fje)
- Zheng L, Zhou Z, Lin L, Alber S, Watkins S, Kaminski N, Choi AM, Morse D (2009) Carbon monoxide modulates alpha-smooth muscle actin and small proline rich-1a expression in fibrosis. *Am J Respir Cell Mol Biol* 41:85–92. doi:[10.1165/rcmb.2007-0401OC](https://doi.org/10.1165/rcmb.2007-0401OC)
- Zhou Z, Song R, Fattman CL, Greenhill S, Alber S, Oury TD, Choi AM, Morse D (2005) Carbon monoxide suppresses bleomycin-induced lung fibrosis. *Am J Pathol* 166:27–37. doi:[10.1016/S0002-9440\(10\)62229-8](https://doi.org/10.1016/S0002-9440(10)62229-8)
- Zuckerbraun BS, Billiar TR, Otterbein SL, Kim PK, Liu F, Choi AM, Bach FH, Otterbein LE (2003) Carbon monoxide protects against liver failure through nitric oxide-induced heme oxygenase 1. *J Exp Med* 198:1707–1716. doi:[10.1084/jem.20031003](https://doi.org/10.1084/jem.20031003)
- Zuckerbraun BS, Chin BY, Wegiel B, Billiar TR, Csizmadia E, Rao J, Shimoda L, Ifedigbo E, Kanno S, Otterbein LE (2006) Carbon monoxide reverses established pulmonary hypertension. *J Exp Med* 203:2109–2119. doi:[10.1084/jem.20052267](https://doi.org/10.1084/jem.20052267)

Gasotransmitters: Physiology and Pathophysiology

Hermann, A.; Sitdikova, G.F.; Weiger, Th.M. (Eds.)

2012, X, 206 p., Hardcover

ISBN: 978-3-642-30337-1